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ABSTRACT

DYNAMIC REGULATION OF MITOCHONDRIAL STAT3 AND ITS ASSOCIAITON WITH
CYPD
By Jeremy Allen Meier
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Director: Andrew C. Larner, Professor, Department of Biochemistry

In recent years, a number of nuclear transcription factors have been shown to be present
in the mitochondria where they have distinct roles in regulating mitochondrial function. Signal
Transducer and Activator of Transcription 3 (STAT3), classically activated by the JAK family of
receptor associated tyrosine kinases to drive nuclear gene expression, is one such transcription
factor with a unique mitochondrial role. There, it has been shown to support oxidative
phosphorylation, regulate mitochondrial-encoded transcripts, and be key for the transformation
and growth of a number of different cancers. Despite its well-characterized functional
importance at the level of the mitochondria, the mechanism through which mitochondrial STAT3
acts and how it is regulated has not been as well studied.
Using various cell culture models, we now show that mitochondrial STAT3 is
dynamically regulated by oxidative stress and cytokine treatment in the acute setting. Under
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these conditions we have observed a rapid loss of mitochondrial STAT3 that recovers to baseline
conditions with time. During this recovery phase we have noted that mitochondrial STAT3
becomes competent to bind to Cyclophilin D (CypD), the key regulator and activator of the
mitochondrial permeability transition pore (MPTP). This is particularly the case with oxidative
insults, where STAT3 seems to play an inhibitory role on MPTP opening, which we believe may
be an important homeostatic mechanism. Intriguingly, chronic stimulation with certain stressors
seems to increase mitochondrial STAT3 levels suggesting differential regulation in the acute
versus chronic setting.
The regulation of mitochondrial STAT3 levels by various stimuli points to a novel
signaling pathway potentially linking mitochondrial responses with those of the cell. Unification
of responses throughout the cell would seem to serve a clear adaptive advantage, particularly in
coupling nuclear regulation with metabolic demands as dictated by the mitochondria.
Extramitochondrial signaling, also known as the mitochondrial retrograde response, has emerged
as an important homeostatic mechanism in lower organisms, but its signaling components have
not been well characterized at the mammalian level. Our results point to a role for mitochondrial
STAT3 in sensing cellular inputs, whereby its regulation and subsequent association with CypD
may have implications in overall mitochondrial quality control. Though the inner workings of
this signaling cascade are just beginning to be elucidated, they suggest the existence of a
previously unappreciated pathway at the mitochondrial level.
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INTRODUCTION

Since their discovery twenty years ago, Signal Transducers and Activators of
Transcription (STATs) have been studied extensively, and are now well-characterized
transcription factors responsible for controlling a diverse array of biological functions. These
proteins have been linked to immune regulation, development, metabolism, cell death, and
tumorigenesis, amongst other cellular roles. There are seven known mammalian STAT family
members (STAT1, 2, 3, 4, 5a, 5b, and 6), and while they have overlapping functions in some
instances, in many cases they have divergent and often opposing roles. Classically, cytokine
activated Janus Kinases (JAKs) tyrosine phosphorylate STATs allowing them to form homo- or
hetero-dimers, which translocate to the nucleus to drive expression of early response genes.
However, non-canonical roles of these transcription factors are emerging that suggests they play
a much broader role in cellular homeostasis than strictly mediating nuclear gene expression.
The discovery that a pool of STAT3 is in the mitochondria, where it exerts an effect on
respiration and Ras transformation (1, 2, 2) , suggests a role of STATs distinct from their
nuclear actions (Figure 1). The following is a summary our current understanding of how the
STAT family of transcription factors regulates mitochondrial function.

Preface: The introduction has been adapted from the following article (copyright license:
3846081475585):

1	
  	
  

Meier JA and Larner AC. Toward a new STATe: The Role of STATs in Mitochondrial
Function. Seminars in Immunology, 2014. 26: 20-28.
All work in this publication was the result of my original work with editing by Andrew C. Larner
and the acknowledgements as originally outlined in the published review.
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Figure 1: Dual Function of STAT3.
STAT3 is classically activated by cytokine or growth factor signaling that drives Janus kinase
(JAK) mediated tyrosine phosphorylation of STAT3 (Tyr-P) that results in its dimerization and
translocation to the nucleus to regulate nuclear gene expression. However, an additional pool of
STAT3 exists in the mitochondria where its function is dependent on serine phosphorylation
(Ser-P) to promote oxidative phosphorylation. Numerous upstream kinases are known to
activate STAT3 via serine phosphorylation suggesting that the regulation of mitochondrial
STAT3 will likely be cell and context dependent. Reprinted from (3) , copyright license:
3851980205684
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I. Signal Transducer and Activator of Transcription 3 (STAT3)
During the past 15 years there have been a number of reports suggesting that a variety of
nuclear transcription factors (TFs) reside in the mitochondria, including NFκB, p53, AP-1,
CREB, MEF2D, and IRF-3 (4, 5) . In most cases, with the exception of p53, the role of these
TFs in mitochondrial function has been limited. Using biochemical fractionation we identified a
small pool of STAT3 (5-10% of total) that is located in the mitochondria of many tissues as well
as cultured cells, where it exerts an effect on Complexes I and II of the electron transport chain
(ETC) [1]. In Ras transformed cells, ATP levels are decreased in the absence of STAT3 and the
activity of Complexes II and V of the ETC are diminished [2]. Through the use of mutants, it
was established that serine 727 of STAT3 is crucial for its mitochondrial function, whereas
known domains required for its nuclear action (tyrosine 705, DNA binding domain, etc.) are not
sufficient to drive STAT3’s mitochondrial action [1,2]. This is intriguing as STAT3 exists as
two predominant forms in the cell: STAT3α and STAT3β, with the latter being an alternative
splice form variant that lacks the S727 phosphorylation site (Figure 2). Hence, it could
potentially serve as a dominant negative mutant in attenuating mitoSTAT3’s action.
Phosphorylation at S727 in STAT3 may also be required for its mitochondrial import, as a serine
to alanine mutation decreased mitochondrial STAT3 levels in an in vitro mitochondrial import
assay (6) . Though there is a much larger fraction of serine phosphorylated STAT3 in the
mitochondria as compared to the cytosol, it is not known whether the entire mitochondrial pool
of STAT3 is constitutively phosphorylated. It is also currently unclear which kinase is
responsible for serine phosphorylation of mitochondrial STAT3. However, a recent report
suggests that mitochondrial serine phosphorylation of STAT3 may be linked to the MEK-ERK
pathway (7) . Additional studies have confirmed and added to the importance of STAT3’s

4	
  	
  

mitochondrial localization, which may have important physiological consequences in the
following areas: metabolism, cancer, and defense against cell stress.

5	
  	
  

Figure 2: STAT3 protein isoforms and their functional domains.
STAT3 exists as two primary isoforms in the cell with STAT3β arising via alternative mRNA
splicing. Key phosphorylation sites are shown to the right of the figure. Importantly STAT3β
lacks the key S727 site that is normally thought to be important for mitoSTAT3 function. N =
N-terminal domain involved in dimerization/tetramerization, CC = coiled-coil domain involved
in interaction with other proteins, DNA = DNA binding domain, LK = linker domain, SH2 =
SH2 domain, Y = phosphotyrosyl tail segment, TA = transactivation domain. Adapted from (8)
, copyright license: 3852001023720.
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A. Mitochondrial STAT3 as a Modulator of Cell Metabolism
STAT3’s contribution to optimal activity of the ETC places this transcription factor in an
ideal position to modulate the energy status of the cell. A number of reports have evaluated the
effect that STAT3 has on the activities of the complexes of the ETC (1, 2, 9-11) , which are
summarized in Table 1. Like the other TFs shown to be present in the mitochondria, the
mitochondrial targeting sequence for STAT3 is likely cryptic and as such, it has yet to be
determined. Therefore, in some studies, in order to better examine its mitochondrial function,
the mitochondrial localization/targeting sequence (MLS/MTS) of human cytochrome c oxidase
subunit VIII (an integral mitochondrial protein) has been fused to the N-terminus of STAT3.
The impact of STAT3 on the ETC varies according to the model used and the context of the
study, but most studies observe an increase in activity in the complexes in the presence of
STAT3. Interestingly, over-expression of a DNA binding domain mutant, STAT3E, targeted to
the mitochondria (MLS-STAT3E) suppresses activities of Complexes I and II (11) . STAT3E
contains two point mutations in the DNA binding domain (E434A/E435A) that are important for
both its recognition and binding of DNA response elements (12) , further excluding nuclear
contributions of STAT3. Under conditions of ischemia, however, over expression of MLSSTAT3E protects the activity of the ETC. This suggests that optimal effects of STAT3 on the
ETC are concentration and stimulus dependent. Perhaps, over-expression of mitochondrial
STAT3 alters its protein-protein interactions such that its actions on the ETC become more
protective under conditions of stress and less effective in regulating the activity of the ETC under
basal conditions. This idea would be consistent with the observations of Phillips and colleagues
that the stoichiometry of mitochondrial STAT3 to components of the ETC is not 1:1 (13) ,

7	
  	
  

which implies that mitochondrial STAT3 may not be modulating the ETC directly. If this is the
case, then it must be doing so via an unknown mechanism whereby the overall levels of STAT3
in the mitochondria would be crucial for determining its binding partners and therefore, its
regulation of mitochondrial function. One possible manner in which STAT3 may be regulating
mitochondrial function, and particularly its effects on the ETC, may be through its control of the
formation of mitochondrial supercomplexes. These respirasomes more efficiently drive oxygen
consumption while sparing the cell from increased ROS production (14) . Interestingly, STAT3
has been shown to be recruited to these supercomplexes, where it is potentially important for
their stability (Figure 3) (15)
As mentioned, mitochondrial STAT3 is also closely associated with cellular ATP levels.
In Ras transformation of mouse embryonic fibroblasts (MEFs), Gough et al showed that the
activity of Complex V (ATP Synthase) of the ETC was dramatically reduced in the absence of
STAT3, thereby limiting ATP production (2) . While not directly linked to Complex V
function, a study using a conditional knockout of STAT3 in astrocytes also observed a
considerable reduction in ATP levels compared to cells expressing STAT3 (16) . Similarly,
blockade of STAT3 activity using the STAT3 inhibitor Stattic has been shown to decrease ATP
production in purified rat heart mitochondria (17) , and in Stattic treated human spermatozoa
(18) . Stattic is a small molecule inhibitor of STAT3 that binds to its SH2 domain that prevents
its activation and dimerization, and also blocks its nuclear translocation (19) . Though the
effects of Stattic on mitochondrial STAT3 have not been carefully investigated, its use on
isolated mitochondria as in the study above (17) suggests that it can also inhibit STAT3’s
mitochondrial action. Further investigation is needed to confirm whether or not STAT3’s
association with ATP is the result of mitochondrial STAT3 affecting Complex V activity, or if it
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is merely a reflection of upstream effects on the ETC. Those upstream effects may partly
explain the lower mitochondrial membrane potential reported in the absence of STAT3 (16, 18)
, which would impact ATP production by reducing the proton gradient across the inner
mitochondrial membrane. It is possible that a nuclear component of STAT3 can also regulate
mitochondrial metabolism because expression of a constitutively active form of STAT3
(STAT3c/c) resulted in decreased mitochondrial membrane potential and ATP generation, likely
due to down regulation of nuclear encoded mitochondrial ETC component mRNA’s (20) . The
functional significance is a metabolic switch towards a more glycolytic phenotype, which is in
contrast to the enhancement of oxidative phosphorylation driven by mitochondrial STAT3. It is
interesting to note the apparent discrepancy between nuclear and mitochondrial-localized STAT3
in terms of regulating mitochondrial function, and while speculative, may point to dual
regulation by these pools of STAT3 to control cellular energy.
While a mechanism regulating STAT3’s ability to monitor and modify the energy status
of the cell is still elusive, there are some indications of signaling cascades operating here. In
Sirtuin 1 knockout (KO) MEFs, there are selective increases in mitochondrial phospho-S727
STAT3 that was found to be downstream of NFκB activation (9) . The kinase responsible for
this increased phosphorylation for serine 727 remains to be determined. Increased activity of
mitochondrial STAT3 was correlated with elevated ETC activity, respiration, and cellular ATP
levels. Sirtuins represent a family of deacetylase proteins that sense the metabolic status of the
cell and regulate the acetylation status of their targets to maintain energy homeostasis, among
other things (21) . It is notable that Sirtuin 1 has been reported to regulate acetylation of STAT3
that plays an important role in gluconeogenesis (22) . Though Sirtuin1 is localized to the
nucleus, Sirtuin 3 is found exclusively in the mitochondria. As Sirtuin 3 affects mitochondrial
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metabolism and function by altering the acetylation state of mitochondrial proteins (23-25) , it is
plausible that it exerts a similar effect on STAT3.
Due to the link between cellular metabolism and physiology, STAT3’s presence or
absence from mitochondria likely has pathological implications. One arena where this may be
the case is in the development of metabolic syndrome, which has close ties with mitochondrial
dysfunction. STAT3 has been shown to be involved in the pathogenesis of obesity and insulin
resistance (26) , and as such, it is an intriguing possibility that part of the pathology seen in
metabolic disorders is influenced by STAT3’s mitochondrial actions. Indirect evidence for this
is presented in a study examining liver specific deletion of src homology phosphatase 2 (Shp2)
(27) . Deletion of Shp2, which plays a role in insulin signaling, prevented the development of
metabolic syndrome in mice exposed to a high fat diet. Interestingly, in the absence of Shp2, the
authors also saw increased activation (phospho-S727) of mitochondrial STAT3, which was
correlated with increased mitochondrial respiration and energy expenditure that limited
metabolic dysfunction. As activation of Shp2 and its phosphatase activity plays a role in
negatively regulating cytokine mediated signal transduction (28) , Shp2’s deletion likely leads to
increased activation of downstream pathways, including the STATs. This may better explain
STAT3’s increased activation, as opposed to impaired insulin signaling, especially when one
considers the positive correlation between high fat diet and circulating cytokine levels such as
IL-6. Further, a study on polymorphisms in the STAT3 gene in human subjects were closely
linked to mtDNA copy number and insulin resistance, whereas variants of known regulators of
the mitochondrial genome, such as TFAM or PPARγ, did not show the same association (29) .
Additional studies are needed to characterize the interplay of mitochondrial and nuclear STAT3
effects in mediating metabolic disease.
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Table 1: STAT3 affects the activities of the ETC complexes.
Summary of the published work on mitochondrial STAT3’s regulation of the electron transport
chain. The results presented in this table showcase the effect that STAT3 has when present in
the mitochondria as some studies have utilized STAT3 null backgrounds as the basis for their
comparison. é: increase in activity; ê: decrease in activity; −: no change in activity; blank:
complex activity not reported on; °MLS-STAT3E: cardiac specific overexpression of
mitochondrial targeted STAT3 containing mutations in the DNA binding domain
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Figure 3: mitoSTAT3 as a regulator of respiratory supercomplexes.
Though initial reports focused on mitoSTAT3’s support of the activities of complexes I, II, and
perhaps complex V of the ETC it is now appreciated that STAT3 can be recruited to respiratory
supercomplexes to promote ETC activity and ATP synthesis without increasing ROS production.
Reprinted from (30) with permission granted by IJBS Publishing Team.
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B. Cancer and Mitochondrial STAT3
STAT3’s mitochondrial localization and influence on energy stores makes it ideally
situated to modify cell growth. As an example, mitochondrial STAT3 is required to drive neurite
outgrowth in response to a variety of ligands including nerve growth factor (31, 32) . Coupled
with the fact that the mitochondrion is the central player in mediating cell death and survival
pathways, mitochondrial STAT3 may play a role in cancer biology. This idea was first
investigated in the context of Ras transformation. HRasV12 expressing MEFs required
mitochondrial STAT3 to drive colony formation in vitro and tumor growth in mice (2) .
Expression of mutant forms of STAT3 in a STAT3 null background demonstrated that serine 727
phosphorylation of STAT3 was necessary to mediate these effects. The serine phosphorylation
of STAT3 via oncogenic Ras was later found to be partially dependent upon Ras activation of the
MEK-ERK pathway as MEK inhibitors were able to interfere in part with mitochondrial
STAT3’s role in Ras tumorigenesis (7) . In contrast, sites crucial for the nuclear actions of
STAT3 (SH2 domain, tyrosine 705 site, DNA binding domain) were not required to drive Ras
transformation. Expression of mitochondrial targeted STAT3 (MTS-STAT3) drove Ras
transformation as efficiently as wild-type STAT3 suggesting that mitochondrial localized STAT3
is sufficient to drive these oncogenic effects. The necessity of mitochondrial STAT3 in Ras
transformation extended to other mutant forms of Ras (KRas and NRas), but not necessarily to
other oncogenes such as vSrc. Since activation of the downstream targets of Ras (Raf/MEK/Erk
and PI3K) were largely unaffected in the absence of STAT3, the mechanism regulating Ras
dependence on mitochondrial STAT3 likely resides in STAT3’s ability to regulate the ETC to
facilitate adequate production of ATP to drive continued cell growth.
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These results were extended by recent work demonstrating that mitochondrial STAT3 is
also important in the growth of already transformed cells (33) . Expression of a mitochondrial
targeted STAT3 (MLS-STAT3) in 4T1 cells, a murine breast adenocarcinoma model, showed
that S727 of STAT3 is also required for optimal cancer cell growth. Mutation of S727 to alanine
leads to decreased colony formation in soft agar, which is mirrored by the development and
progression of tumors in immunocompetent Balbc mice. Tumors expressing MLS-S727A
STAT3 were smaller than their wild-type counterparts and also displayed decreases in the
number of liver and lung metastases. In contrast, expression of the phospho-mimetic mutant
MLS-S727D STAT3 resulted in increased colony formation in vitro, and larger tumors in mice
with a greater metastatic burden. The nuclear effects of STAT3 could largely be excluded as
these constructs contained mutations in the nuclear localization sequence, SH2 domain, DNA
binding domain, and tyrosine 705 sites. The mechanism behind mitochondrial STAT3’s
regulation of breast cancer growth was attributed to optimization of the ETC and control of
reactive oxygen species (ROS) production in a hypoxic environment. Hypoxia features
prominently in the transformation and growth of solid tumors and is tightly coupled to elevations
in mitochondrial ROS production (34) . The relevance of ROS in driving tumorigenesis and
cellular growth has been widely studied, and is thought to be a potential therapeutic target in
cancer therapy (35, 36) . In line with this, cells harboring MLS-S727D STAT3 displayed
elevated Complex I activity of the ETC and decreased ROS production when cultured in 1%
oxygen. However, those cells expressing the S727A mutant had reduced ETC activity and
higher levels of ROS under hypoxic conditions. Interestingly, only tumors from mice expressing
MLS-S727A STAT3 showed a selective growth advantage when mice were injected with the
anti-oxidant Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP).
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These results point to a role of mitochondrial STAT3 in regulating ROS levels as a
determinant of cancer cell growth and proliferation. This makes the mitochondrial pool of
STAT3 a potentially interesting therapeutic target, especially when considering the number of
cancers that display constitutive STAT3 activation. Through the use of a wide array of targeted
inhibitors, numerous studies have demonstrated that blockade of STAT3’s nuclear pro-survival
program is efficacious in promoting cancer cell death (37) Despite this, these compounds have
had little therapeutic value thus far. However, few reports have evaluated how these compounds
affect the mitochondrial program of STAT3. A recent study by Mackenzie and colleagues
demonstrated the importance of targeting mitochondrial STAT3 in pancreatic cancer (38) .
They showed that the anti-tumor activity of their novel compound, phospho-valproic acid (P-V),
depended solely on inhibition of the actions of mitochondrial STAT3, despite also blocking the
STAT3 driven increased expression of the anti-apoptotic proteins Bcl-xl, Mcl-1, and survivin.
Human pancreatic cancer cell lines that expressed a mitochondrial targeted STAT3 (MLSSTAT3) that were orthotopically implanted into nude mice were completely insensitive to the
tumor growth limiting effects of P-V. Over-expression of the dominant negative STAT3 mutant
Y705F also blocked the pro-apoptotic program of P-V thereby lending support to the idea that it
is the mitochondrial pool of STAT3, rather than the nuclear pool, that is sustaining the cells’
oncogenic program. P-V exerted these effects by preventing the mitochondrial localization of
STAT3, which in turn led to a depressed mitochondrial membrane potential, elevated ROS
production, and increased mitochondrial-mediated apoptosis. Targeting mitochondrial STAT3
may therefore, be just as important in limiting cancer growth and survival as blockade of its
transcriptional activity. The importance of mitochondrial STAT3 in pancreatic cancer is not
without precedent as a study by Kang et al showed that STAT3 localized to the mitochondria
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plays a role in advanced glycation end product-specific receptor (RAGE) mediated autophagy
(39) . Autophagy is upregulated in pancreatic cancers basally, which makes the mechanism of
autophagy an attractive therapeutic target (40) . In this study [34], autophagy triggered IL-6
induced serine 727 phosphorylation of STAT3, which was sufficient to increase mitochondrial
STAT3 levels and elevate overall ATP production, likely leading to enhanced tumorigenesis and
cellular proliferation. The absence of RAGE in a KRAS-induced neoplastic model significantly
increased time to tumor development, which was coupled by decreases in mitochondrial STAT3
and its activity with subsequent increased apoptosis and decreased ATP production. Again,
these studies suggest that mitochondrial STAT3 is important in the growth and maintenance of
tumors. While the study by Mackenzie et al implicated JAK2, Src, and HSP-90 with decreases
in phospho- STAT3 and an overall decrease in mitochondrial STAT3 levels, further investigation
is needed to characterize the specific effects and binding partners of mitochondrial STAT3 that
drive these pro-oncogenic processes (38) .
Another study investigating the involvement of STAT3 in pituitary growth and
tumorigenesis also determined that Src may be an upstream regulator of mitochondrial STAT3
activity. In this report, a polymorphism in the fibroblast growth factor receptor led to enhanced
activation of Src, which was correlated with increased levels and activation of STAT3 in the
mitochondria that led to elevated mitochondrial activity as assessed by cytochrome c oxidase
activity (41) . Whether Src’s involvement here is merely an indicator of overall cellular
activation or is specific to initiating a signaling cascade to control STAT3’s actions in the
mitochondria remains unknown.
A recent study had demonstrated that STAT3 interacts with Cyclophilin D (CypD) to
regulate the mitochondrial permeability transition pore (MPTP) (42) . While the structural

	
  
16	
  

components of the permeability transition pore are debated (43-45) , the only protein known to
be absolutely required for pore functioning is Cyclophilin D (CypD), which is thought to be
activated in the mitochondrial matrix and translocate to the inner mitochondrial membrane to
facilitate pore opening (46) . Under non-stressed conditions the pore transiently opens and
closes to maintain calcium concentration gradients and mitochondrial membrane potential.
Sustained opening of the pore due to certain stimuli (ROS, misfolded mitochondrial proteins,
excess Ca2+, etc) leads to mitochondrial swelling, dysfunction, and ultimately, apoptosis or
necrosis (47) . Other TFs, such as p53, can also control cell viability by modulating MPTP
opening through interactions with CypD (48) . Interestingly, the permeability transition pore
more readily opens in the absence of STAT3 or in the presence of the STAT3 inhibitor, Stattic,
thereby implicating STAT3 in MPTP regulation (17, 42) . This may serve as a cytoprotective
mechanism to mitigate cell death and hence be advantageous for cancer cells. This idea is in line
with the work by Mantel et al, who also suggest that STAT3’s regulation of the MPTP may have
pathophysiological consequences in myleoproliferative disorders (49) .
Though it would appear that STAT3 is playing a pro-survival role here, there is one
report that demonstrates that translocation of STAT3 to the mitochondria is actually required for
tumor necrosis factor (TNF) induced necroptosis (50) . As STAT3’s effect on the MPTP was
not investigated in this study, further work is needed to clarify the mechanism through which
STAT3 controls cell viability at the mitochondria.

C. Defense Against Cell Stress
A large body of work on STAT3 and its mitochondrial function lies in the area of
ischemia/reperfusion injury, and the importance that STAT3 may play in preserving cell viability
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and function following myocardial injury, and though not studied as extensively, in the case of
cerebrovascular accident. The importance of STAT3 in this context has been thoroughly
reviewed elsewhere (4, 51) , and hence, will only be briefly discussed. Ischemia triggers
dysfunction of the electron transport chain, which upon reperfusion drives the production of
excess reactive oxygen and nitrogen species (ROS/RNS) that damage mitochondria and the cell.
Therefore, better understanding of the molecular pathways regulating ROS/RNS production
affords the opportunity of maximizing cardio- or neuro-protection. STAT3 is recruited to
mitochondria following ischemic injury (11) , while the pool of mitochondrial STAT3 may be
activated as early as seven minutes post-reperfusion in mouse hearts subjected to ischemia and
reperfusion (52) . Mitochondrial localized STAT3 preserves Complex I activity during ischemia
and reduces ROS production, which is sufficient to limit cytochrome c release, likely preserving
cell viability (11) . Similar results were obtained in a model of ischemic post-conditioning in
porcine hearts (53) . In these studies increases in phospho-Y705 STAT3 in the mitochondria
were directly linked to decreases in infarct size, maintenance of Complex I activity, and
decreased MPTP opening. These protective effects were diminished in the presence of the
STAT3 inhibitor, Stattic. The role of mitochondrial STAT3 in preserving cardiac function may
be more relevant in the context of ischemic post-conditioning, which uses brief, repeated bouts
of ischemia prior to reperfusion in an attempt to limit injury via ROS/RNS induced activation of
pro-survival kinases. In line with this, mice harboring a cardiomyocyte specific deletion of
STAT3 showed no difference in infarct size following ischemia and reperfusion (42) . There
was however a statistically significant difference in infarct size following ischemic
postconditioning, in which STAT3 knockout hearts had larger infarcts than their wild-type
counterparts (54) . In fact, in a rat model, mitochondrial STAT3 activation was not observed

	
  
18	
  

with ischemia/reperfusion, but only with ischemic postconditioning (55) . While not studied in
the context of ischemia, other studies have demonstrated that cardiac disease and injury is
modulated by mitochondrial STAT3. Decreased activation of mitochondrial STAT3 (pS727) is
permissive to the development of cardiac hypertrophy driven by catecholamine injury (56) .
Likewise, decreases in total and phosphorylated mitochondrial STAT3 was correlated with the
pathology seen in a model of dilated cardiomyopathy (57) . In contrast, increased STAT3
activation in mitochondria correlates with improved mitochondrial activity and optimal left
ventricular functioning in a rat model (58) . Additional studies are needed to fully understand
the mechanism and timing behind which mitochondrial STAT3 exerts these protective effects.
The upstream and downstream signaling components that mediate STAT3’s functional
significance in the mitochondria in reperfusion injury/cell stress have remained elusive, though
there are potential targets. The finding that STAT3 may regulate the mitochondrial permeability
transition pore (MPTP) (17, 42) has broad implications in ischemia/reperfusion injuries, as the
MPTP is a major player in cellular injury following this insult (59, 60) . As the MPTP is
activated in response to a number of cellular stressors including ROS and elevated intramitochondrial Ca2+ concentrations (the latter likely due to the tight connection between Ca2+
homeostasis and ROS production), it is possible that oxidative modification of STAT3 in the
mitochondria regulates its association and control of the MPTP. STAT3 has been shown to be Sglutathionylated (61-63) and S-nitrosylated (64) in the cytosol, and it is capable of forming
multimers following an oxidative insult that impinges on its ability to bind DNA (65) . Whether
similar events are modifying STAT3 in the mitochondria and if this has a functional significance
remains to be determined (66) . Under these circumstances, recruitment of STAT3 to the
mitochondria may involve both redox-dependent and redox-independent mechanisms (55) , and
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thus, the mechanism by which STAT3 translocates to the mitochondria is likely stimulus
dependent. More classical signaling cascades have also been linked to mitochondrial STAT3’s
activation and protective effects in the heart. Pre-treatment with the JAK inhibitor AG490 has
been shown to block the reduction in infarct size mediated by STAT3 in ischemia/reperfusion
models (52, 53, 55) . IL-6 mediated signaling may also play a role as it is linked to STAT3
activation during ischemia and is important for cardioprotection (67) . In the absence of heat
shock protein H11 kinase/Hsp22 (Hsp22), a stress response protein that is important for
responses to cardiac overload, both the mitochondrial and nuclear actions of STAT3 were
diminished (68) . Hsp22 was determined to be necessary for STAT3 activation, which was
dependent on NFκB driven IL-6 production, again pointing to IL-6 activation as potentially
upstream of STAT3’s mitochondrial function. Further studies are required to adequately
separate the importance of these signaling cascades in mitochondrial STAT3 function apart from
their effects on STAT3 dependent gene transcription.
Aside from its clear role in the heart, mitochondrial STAT3 may play a role in other
systems in minimizing oxidant cellular stress. A study using a mouse model with a
hematopoietic cell specific deletion of STAT3 demonstrated that the absence of STAT3 leads to
mitochondrial dysfunction and significantly elevated ROS production (49) . The authors
believed that this was likely due to defects in the ETC that led to electron leak and subsequent
elevated mitochondrial and cellular ROS levels. The mitochondrial dysfunction observed
correlated with decreased hematopoietic stem cell reserves, and a shift towards a hematological
makeup that mimicked human myeloproliferative disorders. As these myeloproliferative
diseases are generally seen in older individuals, it is notable that these mice displayed an
accelerated aging phenotype as evidenced by lymphoid-myeloid markers and their dramatically
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reduced lifespan. While not previously addressed, perhaps the absence of mitochondrial STAT3
contributes to the aging process. In fact, mitochondrial STAT3 is reduced in the hearts of older
mice (42) . Considering the link between aging and mitochondrial dysfunction, it is plausible
that reduction in mitochondrial STAT3 levels over time plays a part in this phenomenon.
Therefore, therapeutic strategies designed to maintain STAT3 in mitochondria could prove
fruitful in combating age related disorders.
The similarities between ischemia/reperfusion injuries in the heart and the nervous
system, makes it likely that mitochondrial STAT3 may play an equally important role in
cerebrovascular accidents. STAT3 normally regulates the expression of the manganese
superoxide dismutase (Mn-SOD) gene, a protein that is important in reducing mitochondrial
oxidative species, but that regulation is lost during cerebral ischemia and reperfusion (69) .
However, inactivation of STAT3 with Stattic during ischemia and reperfusion still significantly
increased neuronal cell death and infarct size. While it is clear that the nuclear actions of STAT3
regulate the anti-oxidant status of the cell basally, it is possible that STAT3 translocates to the
mitochondria following oxidative injury to regulate mitochondrial function directly to limit ROS
production and maintain cell viability. Perhaps then, inactivation of STAT3 in this model limits
its mitochondrial translocation, and may explain in part the increase in neuronal cell death
observed following Stattic treatment. STAT3 is also required to maintain mitochondrial
membrane potential and limit cell death in lung epithelial cells exposed to hyperoxia (70) .
Again, while this study did not directly investigate mitochondrial STAT3’s actions, it suggests
that STAT3 may protect the cell from oxidative stress by its actions in both the nucleus and the
mitochondria.
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D. Summary
The role of STAT3 in regulating mitochondrial function is summarized in Figure 4.
Though not currently known, it is likely that upstream activation of signaling cascades by
cytokines, growth factors, and/or oxidative stress is involved in STAT3’s targeting to the
mitochondria. Due to the association of S727 phosphorylation with STAT3’s mitochondrial
function, a number of signaling cascades known to activate STAT3 at this residue (including
ERK, JNK, p38 MAPK, Protein Kinase C, mTOR, etc.) (71) also probably play a role in
STAT3’s mitochondrial action with the particular kinase involved being stimulus and cell-type
specific. Within the mitochondria STAT3 modulates two major players in mitochondrial
physiology: the ETC and MPTP. This tends to result in increased mitochondrial membrane
potential (ΔΨ), increased ATP production, decreased ROS levels, and decreased cell death.
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Figure 4: Model of STAT3’s Mitochondrial Action. Upstream activation by cytokines,
growth factors, or oxidative stress likely post-translationally modifies STAT3 to target it to the
mitochondria. Though still unknown, mitochondrial import of STAT3 may rely on translocases
of the outer membrane (TOM20 potentially) and GRIM-19 in the inner mitochondrial
membrane. Once imported, STAT3 modulates both the electron transport chain (ETC) and the
mitochondrial permeability transition pore (MPTP) to regulate mitochondrial membrane
potential (ΔΨ), ATP production, ROS production, and cell death. OMM: Outer Mitochondrial
Membrane; IMM: Inner Mitochondrial Membrane
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II. Other STATs with Known Mitochondrial Function
Although STAT3’s actions in the mitochondria have been the most studied, there is
evidence from the literature and unpublished results that points to the importance of other STAT
family members in mitochondrial function. Aside from STAT3, other STATs (STAT1, STAT2,
STAT5, and STAT6) have been shown to localize to the mitochondria. Their mitochondrial
actions are discussed below and are summarized in Table 2.

A. Signal Transducer and Activator of Transcription 1 (STAT1)
In contrast to STAT3, which is a well-known negative regulator of the mitochondrial
apoptotic program (based on its control of Bcl-2 family member protein expression), STAT1 is a
prominent player in pro-apoptotic signaling (72-74) . While most of the actions of STAT1 are
attributed to its role as a TF, STAT1 has been reported to localize to the mitochondria (42) .
Results from our lab have confirmed that STAT1 is present in the mitochondria from a variety of
tissues and cell types, but its exact functional significance there is still unclear (75) . As a key
mediator of interferon (IFN) signaling, our results suggest that mitochondrial localized STAT1
may play a role in downregulating the transcription of mitochondrial encoded RNA’s, while also
negatively controlling nuclear encoded transcripts of the electron transport chain in response to
IFNβ but not IFNγ. The reduction of mitochondrial encoded RNA’s in the presence of IFNβ
occurs even in platelets, which lack nuclei, and was abrogated in STAT1 null platelets. In vitro
transcription assays demonstrated that STAT1 could inhibit mitochondrial transcription on both
the heavy and light strands of the mitochondrial genome, albeit to a lesser extent on the light
strand (Sisler JD et al, unpublished results). Interestingly, starvation reduces STAT1 protein
levels in tissues that leads to increased mitochondrial biogenesis, which correlates with data
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obtained from STAT1 knockout mice that display elevated levels of mitochondrial biogenesis
compared to wild type mice (75) . Further work is ongoing to clarify the role that
mitochondrial STAT1 plays in regulation of mitochondrial content.

B. Signal Transducer and Activator of Transcription 2 (STAT2)
A study by Goswami and colleagues demonstrated that translocation of STAT2 to
mitochondria could be mediated by viruses in an attempt to alleviate the cells anti-viral response
(76) . STAT2 activation features prominently in interferon induced anti-viral cell defense. In
this context, they examined the role of viral targeting of the mitochondrial antiviral signaling
adaptor (MAVS) in suppressing innate immunity. The viral non-structural (NS) proteins NS1
and NS2, with the help of MAVS, drive the formation of a degradasome at the mitochondria,
which was responsible for targeting the cell’s anti-viral protein repertoire to the mitochondria for
degradation, which included STAT2. Though the authors focused on the pool of STAT2 that
was degraded in the mitochondria by the formation of the viral degradasome, there was a small
fraction of STAT2 that basally resided in the mitochondria of the lung epithelial adenocarcinoma
A549 cell line. With the emergence of mitochondria as an important player in innate immunity
by controlling the cell’s energy and oxidation status (77) and STAT2’s role in immune defense,
it is possible that mitochondrial localized STAT2 could also contribute by priming mitochondria
for an immune response. Unpublished results from our lab also indicate that a small pool of
STAT2 basally resides in the mitochondria (Sisler JD et al). Here it may selectively negatively
regulate the transcription of mitochondrial RNAs. Mitochondrial encoded mRNA transcripts are
increased in the absence of STAT2, but unlike STAT1, no effect was observed on nuclear
encoded mitochondrial mRNA’s or on mitochondrial biogenesis (Sisler JD et al, unpublished
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results). The importance of these findings remains to be determined. Nevertheless, it points to a
much broader regulation of cellular homeostasis by these transcription factors.

C. Signal Transducer and Activator of Transcription 5 (STAT5)
There is limited knowledge about the role of STAT5 in mitochondrial function. One
report has shown its localization to the mitochondria in a murine T lymphoma cell line, where it
associates with the E2 component of pyruvate dehydrogenase (78) . The authors also reported
STAT5 translocation to the mitochondria following cytokine stimulation (IL-2 treatment of the
human leukemia cell line CLL-20 and IL-3 treatment of the murine pro-B cell line BaF3).
Cytokine induced targeting of STAT5 to the mitochondria was specific as neither STAT1 nor
STAT3 was recruited to the mitochondria under these conditions. STAT5 was shown to bind to
the D loop of mitochondrial DNA, but the actions of STAT5 on mitochondrial gene expression
have not been delineated. Due to the switch to aerobic glycolysis that was observed in these cell
lines upon mitochondrial STAT5 translocation, the authors speculated that STAT5 might be
playing a role here in regulating mitochondrial metabolism in cancer cells. Considering the role
that STAT5 plays in cancer, this study is consistent with an analogous role for STAT5 as STAT3
in driving tumorigenesis via its actions in the mitochondria. As this study did not differentiate
between STAT5a and STAT5b, which have both redundant and unique biological actions, more
work is needed to fully understand mitochondrial localized STAT5’s role and function.

D. Signal Transducer and Activator of Transcription 6 (STAT6)
To date only one report indicates that STAT6 localizes to the mitochondria. Khan and
colleagues demonstrate the association of STAT6 with mitochondria in a variety of cells using

	
  
26	
  

immunofluorescence (79) . The use of immunogold electron microscopy in human pulmonary
artery endothelial cells showed the constitutive presence of STAT6 in the mitochondria. This
was further validated using live-cell imaging. Interestingly, only the N-terminal half of STAT6
was required for its mitochondrial localization indicating that the SH2 domain and tyrosine 641
phosphorylation site are not needed for its targeting to this organelle. Though this work provides
compelling evidence for STAT6 in the mitochondria, the functional significance of STAT6’s
localization here was not explored and warrants further investigation.
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Table 2: Role of STATs in Mitochondrial Function. Members of the STAT family of proteins
with known mitochondrial actions.

Mitochondrial Function
STAT1

! Regulation of mitochondrial biogenesis
! Negative regulation of mitochondrial encoded transcripts

STAT2

! Negative regulation of mitochondrial encoded transcripts
! Mitochondrial translocation as a target of viral NS degradasome

STAT3

! Regulation of the ETC, cellular respiration, and mitochondrial membrane potential
!
!
!
!
!

Reference
[75]
Sisler JD and M Morgan et al, unpublished

Modulation of mitochondrial ROS production
Association with ATP production
Transformation and cellular growth
Inhibition of mitochondrial permeability transition pore
Protection against ischemia/reperfusion and cardiac injury

! TNF induced necroptosis
! mtDNA and Transcript Regulation

Sisler JD et al, unpublished
[76]
[1],[2],[5],[7], [9],[10], [15],[16],[17],[18],
[20],[27],[38],[42],[49],[53],[58],
[11],[33],[38],[41],[49]
[2],[16],[17],[18],[20],[39]
[2],[6],[31],[32],[33],[38],[39],[41], [157]
[17],[42],[53],[139]
[11],[17],[42],[52],[53],[54],[56],[57],[58],
[68],[139]
[50]
[107],[141]

STAT5

! Cytokine mediated mitochondrial translocation and binding of the D-loop of mitochondrial DNA

[78]

STAT6

! Shown to co-localize with mitochondria using both fluroescence and electron microscopy

[79]
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III. Conclusions on the State of mitoSTAT’s
The increasing number of reports that link STATs and other TFs with the mitochondria
demonstrate both the relevance and importance of a careful investigation of their function in this
subcellular organelle. Though new actions of these proteins in the mitochondria are being
unveiled, fundamental questions still remain unanswered. When one considers their relative low
abundance in the mitochondria and the limitations of cell fractionation, delineation of the
mitochondrial targets of STATs is challenging. There are also likely inherent differences in the
amounts of these proteins present in the mitochondria depending upon the tissue or cell type
studied and whether or not the cells are stressed. These factors likely contribute to the
discrepancies in detection of STAT3 in the mitochondria. This has been particularly the case
with fluorescent-based approaches (79, 80) . Similar differences in STAT5’s mitochondrial
localization have also been reported (42, 78) .
The general mechanism by which these proteins are differentially trafficked to
intracellular compartments and organelles remains unknown, despite their broad intracellular
distribution. STATs, like the other nuclear TFs with roles in the mitochondria, lack a classical
mitochondrial localization sequence. Most studies of STAT3 demonstrate selective
accumulation of phospho-S727 STAT3 in the mitochondria, though reports of tyrosine
phosphorylated STAT3 also exist, suggesting other regulatory modifications might be involved.
It hasn’t been carefully explored whether or not tyrosine phosphorylation of STAT3 in the
mitochondria occurs in the absence of serine phosphorylation or if there is any difference in
STAT3’s mitochondrial action depending upon its phosphorylation status. Based on studies
where the serine site in STAT3 has been mutated to an alanine to render it phospho-null (1, 2, 7,
33) it would appear that phosphorylation of S727 in STAT3 is required for its mitochondrial

	
  
29	
  

action. Though the role of tyrosine phosphorylated STAT3 in mitochondrial function is unclear,
it is known to not be required for STAT3 to regulate respiration, Ras-dependent transformation,
or for tumor growth of breast cancer cells (1, 2, 33) . Phosphorylation of STAT5 (78) and
STAT1 (Sisler JD et al, unpublished results) might also be required for their mitochondrial
targeting. However, phosphorylation of STAT6 was not required for its accumulation in the
mitochondria (79) . In the case of p53, a nuclear transcription factor with distinct roles in the
mitochondria (4) , its trafficking has been suggested to be dependent on Pin1, a cytoplasmic
peptidyl-prolyl cis-trans isomerase. Isomerization of proline bonds by Pin1 has been implicated
as being important for regulation of protein function and intracellular localization (81) , and
absence of Pin1 attenuates the recruitment of p53 to the mitochondria (82) . STAT3 has been
shown to interact with Pin1 (83, 84) , suggesting that Pin1 may represent one mechanism
through which STAT3 is transported to the mitochondria.
Once at the mitochondria, the import of STATs represents another crucial regulatory step,
as most proteins that enter the mitochondria must be first unfolded. Typically, the re-folding and
maturation into functional proteins depends on the mitochondrial family of heat shock proteins
(HSPs). Other nuclear transcription factors have been shown to interact with these HSPs
presumably as part of their mitochondrial targeting and maturation following import (4) . It
remains to be determined whether HSPs play a similar role in determining STAT mitochondrial
function, though considering STAT3’s localization to the inner mitochondrial membrane and
matrix it is likely that some chaperone protein is required. GRIM-19, a component of Complex I
of the ETC, has been shown to facilitate import of STAT3 into mitochondria (6) , but it is
probable that other proteins are involved, such as translocases of the outer membrane (TOM), of
which STAT3 is known to interact with TOM20 (see Figure 4) (42) . In order to better

	
  
30	
  

understand the function of STATs in the mitochondria the mechanism behind their mitochondrial
targeting and import needs to be more fully addressed.
Lastly, how STAT protein levels are regulated in the mitochondria is also not clear. In
particular, the signaling cascades that acutely affect mitochondrial STATs has not yet been
explored. The idea of inter-organelle communication may feature prominently in this regulation.
Notably, knockdown of the mitochondrial matrix protein CypD leads to constitutive activation of
cytosolic STAT3 leading to its nuclear localization (85) , and recent results from our lab
demonstrated that expression of a mitochondrial targeted STAT3 construct led to nuclear
activation of endogenous STAT3 protein (33) . This points to the idea of a mitochondrial
retrograde signaling pathway potentially mediated by STAT3 and CypD. Mitonuclear
communication is emerging as an important quality control mechanism in mitochondrial biology,
and while the signaling components of this pathway have been teased out in lower organisms, the
mammalian counterpart is currently unclear (Figure 5). Whether nuclear localized STAT3 could
be exerting a similar effect on the mitochondrial pool of STAT3 requires further investigation.
Even if this intracellular signaling is not responsible for determining levels of STATs in the
mitochondria, it points to a much broader network of communication. Coordinate regulation and
communication between the nucleus and mitochondria would serve a clear adaptive advantage,
especially in the context of cellular proliferation and survival. As more information becomes
available, we will be better equipped to understand the emerging role that the STAT family of
transcription factors has on mitochondrial function.
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Figure 5: Mitonuclear Feedback.
a | In worms, the CLPP-mediated cleavage of unfolded proteins in mitochondria initiates
mitochondrial unfolded protein response (UPRmt) signalling. The efflux of short peptides through
the mitochondrial transporter HAF-1 somehow inhibits mitochondrial protein import and,
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consequently, the transcription factor ATFS-1 (activating transcription factor associated with
stress 1), which is normally imported into mitochondria and degraded by the LON protease
(LONP), translocates into the nucleus. Here, together with ubiquitin-like 5 (UBL-5) and DVE-1,
it induces the expression of UPRmt target genes — namely, those encoding chaperones and
proteases — to restore proteostasis. ATFS-1 can also positively regulate glycolysis and assembly
of the oxidative phosphorylation (OXPHOS) system and negatively regulate the expression of
tricarboxylic acid (TCA) cycle and OXPHOS genes. In response to mitochondrial stress, splice
variants of ATFS-1 accumulate in mitochondria and repress the expression of mitochondrial
OXPHOS genes. b | In mammals, the activation of JUN by c-Jun N-terminal kinase 2 (JNK2)
leads to the induction of CEBP homologous protein (CHOP) and CCAAT/enhancer-binding
protein-β (CEBPβ), which heterodimerize and activate UPRmt genes. Mitochondrial proteotoxic
stress also activates sirtuin 3 (SIRT3), which deacetylates forkhead box transcription factor
FOXO3A, causing its translocation to the nucleus to induce the expression of reactive oxygen
species (ROS) detoxification and mitophagy genes. The import of steroidogenic acute regulatory
protein (StAR) from the mitochondrial outer membrane into the matrix induces, through an
unknown mechanism, the expression of several proteases, which subsequently clear StAR from
mitochondria. Heat causes single-stranded DNA-binding protein 1 (SSBP1) to translocate into
the nucleus, in association with heat shock factor 1 (HSF1), to bind the chromatin modifier
BRG1 and induce the expression of mitochondrial and cytosolic chaperones. AFG3L2, AFG3like protein 2; HSP, heat shock protein; mtDNA, mitochondrial DNA; MURE, mitochondrial
unfolded response element; SPG7, spastic paraplegia 7; YME1L1, YME1-like protein 1.
Reprinted from (86) , copyright license: 3852070120003
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IV. Dissertation Objective
The primary goal of this project was to determine how mitoSTAT3 levels are controlled,
and investigate the relevant protein-protein interactions of mitoSTAT3, both of which might help
to clarify its functional role at the mitochondria. Though a wealth of data exists on STAT3’s
importance in key mitochondrial activities such as ETC regulation, ATP production, and mtDNA
regulation, there has yet to be a clear study on the regulation of mitoSTAT3, particularly in the
acute setting. Using past knowledge in the field that mitoSTAT3 interacts with CypD and
considering mitoSTAT3’s importance in dampening mitochondrial ROS production, we initially
hypothesized that under a ROS stimulus mitoSTAT3 would inducibly bind to CypD. We
anticipated that this would serve as a cytoprotective mechanism in mitochondrial adaptation to
stress. With this in mind we thought that STAT3 might be recruited to the mitochondria under
conditions of stress. This opened the door to an unexpected finding that mitoSTAT3 levels are
dynamically regulated under a number of stimuli. Hence, the regulation of this novel-signaling
pathway involving mitoSTAT3 became the focus of the investigations presented herein.
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MATERIALS AND METHODS

I. Cell Culture
The following cell lines were used in this study: Wild-type Mouse Embryonic Fibroblasts
(MEFs), STAT3-/- MEFs, CypD-/- MEFs, ClpP+/+ MEFs, ClpP-/- MEFs, 4T1 murine breast
adenocarcinoma cells, MDA-MB-231 triple negative human breast cancer cells, WI-38 human
lung fibroblasts, MCF-7 ER+ human breast cancer cells, HCT116 human colorectal cancer cells,
SKOV3 human ovarian cancer cells, U-266 human multiple myeloma cell lines, SKBR3 HER2+
human breast cancer cells, BT474 HER2+ human breast cancer cells, MDA-MB-453 HER2+
human breast cancer cells, MDA-MB-468 triple negative human breast cancer cells, T47D ER+
human breast cancer cells, 293T human embryonic kidney cells, HeLa human cervical cancer
cells, and A549 lung adenocarcinoma cell lines. The human breast cancer cell lines were kindly
provided by Drs. Gordon Ginder, Charles Clevenger, and Frank Fang, Virginia Commonwealth
University. Multiple myeloma cell lines used for the study were provided by Dr. Yun Dai,
Virginia Commonwealth University. WI-38 human lung fibroblasts were provided by Dr. Swati
Deb, Virginia Commonwealth University. HeLa cells were provided by Dr. Thurl Harris,
University of Virginia. CypD-/- MEFs were kindly provided by Dr. Ute Moll, Stony Brook
University. ClpP+/+ and ClpP-/- MEFs were kindly provided by Dr. Georg Auburger, Goethe Universität. Cells were routinely grown in appropriate growth culture (DMEM, DMEM F-12, or
RPMI) media supplemented with 10% heat inactivated Fetal Bovine Serum (Serum Source
International, Charlotte, NC) and 50U/mL Penicillin and 50ug/mL Streptomycin (Life
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Technologies). For ER+ human breast cancer cell lines and studies done inter-comparing breast
cancer lines of different hormone receptor status, media free of phenol red was used to avoid
activation of the estrogen receptor. Prior to experimental use cell lines were tested and found to
be free of mycoplasma contamination.
II. Reagents
The following chemicals and inhibitors were used for the studies: Ruxolitinib (JAK inhibitor,
5µM, Selleck Chemicals), PD0325901 (MEK inhibitor, 10µM, Selleck Chemicals), Saracatanib
(Src inhibitor, 10µM, Selleck Chemicals), BI-D1870 (RSK inhibitor, 10µM, Selleck Chemicals),
Rapamycin (mTOR inhibitor, 50µM, Cell Signaling), LY294002 (PI3K inhibitor, 25µM, Cell
Signaling), SB203580 (p38 MAPK inhibitor, 10µM, Calbiochem), SP600125 (JNK inhibitor,
50µM, Cell Signaling), Torin 1(mTOR inhibitor, 10µM, Tocris Biosciences), Bafilomycin A
(Autophagy inhibition, 1µM, Sigma), Cyclosporine A (Cyclophilin inhibitor, 5µM or 10µg/mL,
Sigma), Oligomycin A (Complex V inhibitor, 10µM, Tocris Biosciences), Antimycin A
(Complex III inhibitor, 4µM, Sigma), Cycloheximide (Protein synthesis inhibitor, 50µg/mL, MP
Biomedicals), Staurosporine (Tyrosine Kinase inhibitor, 100nM, Sigma), H7 Dihydrochloride
(Protein Kinase A/C/G inhibitor, 20µM, Sigma), Cryptotanshinone (STAT3 inhibitor, 10µM,
Selleck Chemicals), Puromycin (Mammalian selection antibiotic, 2µg/mL, ThermoFisher
Scientific), Blasticidin (Mammalian selection antibiotic, 5µg/mL, ThermoFisher Scientific),
mito-TEMPO (mitochondrial anti-oxidant, 100µM, Sigma), Wortmannin (PI3K inhibitor, 2µM,
Cell Signaling), MG132 (Proteasome Inhibitor, 10µM, Tocris Biosciences), Thapsigargin
(SERCA [ER calcium uptake] inhibitor, 1µM, Tocris Biosciences), MDL-28170 (Calpain
Inhibitor, 10µM, kind gift from Dr. Ed Lesnefsky), CDDO-Me (Lon Protease Inhibitor, 5µM,
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Sigma), recombinant murine IL-6 (50ng/mL, Peprotech), recombinant human IL-6 (50ng/mL,
Peprotech), soluble human IL-6Rα (50ng/mL, Peprotech), human OSM with carrier (12.5ng/mL,
Cell Signaling), mouse OSM with carrier (12.5ng/mL, Cell Signaling), recombinant human
GCSF (50ng/mL, Peprotech) IFNβ (5000U/mL, NIH), mouse and human IFNγ (Peprotech,
10ng/uL), mouse and human EGF (50ng/mLGemini BioProducts) λ phosphatase (per
manufacturer’s instructions, NEB), Na3VO4 (Tyrosine Phosphatase Inhibitor, 1mM, Sigma),
Hydrogen Peroxide 30% Solution (1mM unless otherwise indicated, Sigma), cOmplete protease
inhibitor cocktail (per manufacturer’s instructions, Roche), phosSTOP phosphatase inhibitor
cocktail (per manufacturer’s instructions, Roche). All other chemicals used for buffer
formulations were purchased from Sigma-Aldrich or Fisher Scientific unless otherwise indicated.
III. Treatments
All stimulations were carried out in cells cultured in full serum media (10%) so as to avoid any
effect of serum starvation on mitoSTAT3 levels. Aside from protease inhibitor studies (4H pretreatment), all other inhibitors were pre-incubated on cells for no more than 1H prior to H2O2 or
cytokine treatment. Vehicle or DMSO treatments were used when appropriate as controls.
IV. Plasmids
pGEX-CypD and human pHA-CypD were a kind gift from Dr. Ute Moll, Stony Brook
University (48) . pRC-CMV STAT3, pRC-CMV STAT1, pRC-CMV STAT3/1H, pRC-CMV
STAT3/1S, pRC-CMV STAT1/3H, and pRC-CMV STAT1/3S were a kind gift from Dr. Peter
Shaw, Nottingham University (65) . STAT3 deletion constructs were generated via mutagenesis
reaction using pRC-CMV STAT3 as a template according to the manufacturer’s protocol (Quick
Change Lightning Multi-Site Mutagenesis Kit, Agilent Technologies, #210514). The following
forward primers were used to generate the STAT3 N-terminal deletion constructs:
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Δ28:CTCACTATAGGGAGACCCAAGCTTGACCACCATGGAGCTGCGGCAGTTCCTGGC
, Δ50:CTCACTATAGGGAGACCCAAGCTTGACCACCATGGAGTCACATGCCACGTTGG,
Δ100:CTCACTATAGGGAGACCCAAGCTTGACCACCATGGAAATTGCCCGGATCGTGG
CC, Δ138:CTCACTATAGGGAGACCCAAGCTTGACCACCATGGAGAAGCAGCAGATGT
TGG. For STAT3 fragment construction, STAT3 cDNA was amplified from pRC-CMV STAT3
using PfuUltra II Fusion DNA polymerase according to the manufacturer’s instructions (Agilent
Technologies) using the following forward and reverse primers:
STAT3 F: ATAAGAATGCGGCCGCGACCAGCATGGCTCAGTGGAACCAG, STAT3 1138R: CCAGCGGGCCCTCATTTATCGTCATCGTCTTTGTAGTCTGTCACTACGGCGGC,
STAT3 1-150R:
CCAGCGGGCCCTCATTTATCGTCATCGTCTTTGTAGTCATCCTGAAGATGCTG,
STAT3 1-200R:
CCAGCGGGCCCTCATTTATCGTCATCGTCTTTGTAGTCCATCTTCTGTCTGGTC.
After amplification, products were digested with ApaI and NotI (NEB) and gel purified
(QIAquick Gel Extraction Kit) with ligation (DNA Ligase, NEB) into pRC-CMV.
MSCV-IRES-GFP expression vectors containing STAT3α, STAT3β, STAT3 Y705F, STAT3
S727A, STAT3 S727D, MLS-STAT3 and the Phoenix helper construct have been previously
described (1) . Mitochondrial-targeted YFP was a kind gift from Dr. David Kashatus,
University of Virginia (87) . mCherry-Parkin was purchased from Addgene ((88) , plasmid
#23956).
shRNA’s against STAT3 were cloned into pLKO.1 (kind gift from Dr. Thurl Harris, University
of Virginia) between the AgeI and EcoRI sites following restriction digest and gel purification as
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described above. The targeting sequences against human STAT3 were 1) hSTAT3 468-486:
TGTTCTCTATCAGCACAAT and 2) hSTAT3 1063-1081: CTTCAGACCCGTCAACAAA.
pcDNA3.1 6X Myc-STAT3 WT, pcDNA3.1 6X Myc-STAT3 4KR, and pcDNA3.1 6X MycSTAT3 6KR expression vectors were a kind gift from Dr. Tamas Horvath, Yale University (22)
. shRNA against ClpP protease has been previously described (89) and was purchased from
Sigma.
V. Recombinant Proteins
pGEX-CypD and pGEX vectors were transformed into BL-21(DE3) competent bacteria.
Bacterial clones containing the plasmid of interest were grown up overnight in 25mL of LB
media and the following morning back-diluted 1:15 into a 500mL culture. Bacteria were grown
up until OD600 reached 0.6 at which point protein expression was induced with 1mM IPTG for
6H. The bacteria were pelleted and lysed in bacterial lysis buffer followed by sonication. The
bacterial cell extract was then incubated with glutathione sepharose 4B beads (GE Healthcare,
#17-0756-01) for 1H at 4oC. Bead bound GST proteins were pelleted and washed 3X in
bacterial lysis buffer prior to storage at -80oC. A portion of the purified proteins were resolved
via SDS-PAGE and gels were fixed and stained via Coomassie for quantification of GST
recombinant proteins as compared to a BSA standard curve.
STAT3 protein was generated via a rabbit reticulocyte in vitro translation system (Promega,
TM232) according to the manufacturer’s protocol and with the use of the indicated constructs.
Recombinant unphosphorylated and phosphorylated Flag-STAT3 protein was a kind gift from
Claudia Mertens, Rockefeller University, Darnell Lab (90) .
VI. Animals
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Animals were treated in compliance with the Guide for the Care and Use of Laboratory Animals
under the protocols approved by Virginia Commonwealth University Institutional Animal Care
and Use Committee.
VII. 4T1 In Vivo Tumorigenesis Model and Metastatic Cell Selection
4T1 murine breast adenocarcinoma cells were implanted in the mammary fat pad of female
BALB/c mice as previously described (33) . Briefly 2.0 X 104 4T1 cells in PBS/Matrigel were
injected into the mammary fat pad following surgical incision and fat pad exposure. Drs. Ali
Raza and Akimitsu Yamada from Dr. Kazuaki Takabe’s lab performed tumor implantations.
Tumors were allowed to grow for 7 days at which point animals were treated with Doxorubicin
(q3d or q7d, 5mg/kg, Sigma) or PBS vehicle for three weeks or until animal end point
parameters were reached and the animals were sacrificed. Primary tumor and organs with high
metastatic potential (lung and liver) were excised and flash frozen for future analysis.
Mitochondria from primary tumors was isolated as described above for crude mitochondria.
Metastatic cells from livers of tumor bearing mice were finely minced and digested in 5 ml of
enzyme cocktail containing 1xPBS, 0.01% BSA, 1 mg/ml hyaluronidase, and 1mg/ml type I
collagenase for 20 min at 37°C. Lung samples were minced and digested in enzyme cocktail
containing 1xPBS, 1 mg/ml collagenase type IV at 6 units/ml for 75 min at 4°C. After
incubation, samples were filtered through 70-µm nylon cell-strainers and washed three times
with 1xPBS. Cells were plated at a series of dilutions on 10-cm tissue-culture dishes in DMEM
containing 60 µM 6-thioguanine as 4T1 cells are resistant to 6-thioguanine (91) .
VIII. SDS-PAGE and Immunoblotting
Cell samples were lysed in 20mM HEPES, pH 7.4, 300mM NaCl, 10mM KCl, 1mM MgCl2,
20% glycerol, and 1% Triton X-100. After incubation for 15minutes on ice the lysates were
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cleared via centrifugation at 13000rpm for 5min. Equal volume of cell lysate was combined with
2X Laemmli SDS buffer (Bio-Rad, #161-0737) and boiled for 5min. at 95oC. Equal protein (as
quantified by spectrophotometric absorbance at 595nm with Bio-Rad Protein Assay dye reagent,
#500-006) was loaded on Tris-glycine gels and subjected to SDS-PAGE electrophoresis. Gels
were transferred to PVDF membranes (Millipore, IPVH00010) using a semi-dry transfer
apparatus (Bio-Rad, 1703940). The following antibodies were used overnight at 4oC with
shaking at the following concentrations following blocking for 1H in 5% milk or 5% BSA in 1X
TBS + 0.1% Tween-20: STAT3 (Cell Signaling #9139, mouse monoclonal, clone 124H6),
STAT3 (N-terminal, BD Biosciences, mouse monoclonal), STAT3 (Cell Signaling, rabbit
polyclonal), pY705 STAT3 (Cell Signaling, mouse monoclonal), pS727 STAT3 (Cell Signaling,
rabbit polyclonal), Complex V Subunit I (Abcam, mouse monoclonal), STAT1 (BD Biosciences,
mouse monoclonal), pY701 STAT1 (Cell Signaling, rabbit polyclonal), CypD (Abcam, mouse
monoclonal), Calreticulin (Cell Signaling, rabbit polyclonal), Histone H3 (Cell Signaling, mouse
monoclonal), Lamin A/C (Cell Signaling, mouse monoclonal) ATP5O (Abcam, mouse
monoclonal), GRIM19 (Abcam, mouse monoclonal), pAkt (Cell Signaling, rabbit polyclonal),
pc-Jun (Cell Signaling, rabbit polyclonal), NDUFA9 (Abcam #ab14713, mouse monoclonal),
ERK1/2 (Cell Signaling, rabbit polyclonal), Acting (Cell Signaling, mouse monoclonal),
pERK1/2 (Cell Signaling #9101, rabbit polyclonal), Tubulin (Sigma #T8203, mouse monoclonal,
α-Tubulin).
Secondary antibodies were used at a concentration of 1:5000 for 1H at room temperature in 5%
milk in 1X TBS + 0.1% Tween-20: 1) ECL Mouse (Whole) IgG HRP from sheep (GE
Healthcare, Amersham Life Sciences #NA931) 2) ECL Rabbit (Whole) IgG HRP from donkey
(GE Healthcare, Amersham Life Sciences #NA934).
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After washing, blots were incubated with Amersham ECL (GE Healthcare, RPN2106) or ECL2
Western Blotting (Thermo-Scientific, 80196) chemiluminescent detection reagents and
developed using CL-X Exposure Film (ThermoFisher Scientific, #34091) and an autoradiograph
cassette (Fisher Scientific, #FBAC 810). Where indicated densitometry quantification was
performed using ImageJ Software (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2015).
IX. Mitochondrial Isolation
Pure mitochondria separated from their tightly coupled mitochondrial associated membranes
were generated over a Percoll gradient as previously described (Figure 6) (92) . For crude
mitochondrial isolation, adherent cells were treated and then washed with ice cold 1X PBS,
trypsinized, and collected with ice-cold full serum media. Cells were spun down for 5min. at
1000RPM and the pellets were washed 1x with 3mL’s of ice cold 1X PBS. Cells were spun
down again for 5min. at 1000RPM and the supernatant was aspirated off. The cell pellets were
resuspended in an appropriate volume of sucrose buffer (10mM HEPES, pH 7.4, 250mM
sucrose, 1mM EDTA, protease and phosphatase inhibitors) and incubated on ice for 10min.
Cells were then added to a metal douncer (all steps on ice) and cells were homogenized with
manual strokes until roughly 90% of the cells were broken (verify using Trypan blue during the
course of the douncing). Cells were collected and spun down for 5min. at 800g at 4oC to pellet
unbroken cells and nuclei. The supernatant was collected and spun down for 10min. at 8800g at
4oC to pellet crude mitochondria. The supernatant was again collected and transferred to a new
tube labeled cytosolic fraction, which was spun down for 10min. at 10000g at 4oC to remove any
organellar contaminants from the cytosolic sample. After this spin the cytosolic supernatant
(700µL) was transferred to a new tube and frozen at -80oC until further analysis. The crude
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mitochondrial pellet from above was resuspended in 490µL sucrose buffer and 10µL of a
5mg/mL stock solution of trypsin was added to each tube (for a final concentration of
100µg/mL). Samples were then rotated for 10min. at 4oC after which 500µL of a 5% BSA
solution was added to each tube to inactivate the trypsin. Samples were again rotated for 1min.
at 4oC and then spun down at 10000g for 10min. at 4oC. The supernatant was aspirated off
(including the trypsin digested material surrounding the mitochondrial pellet) and the
mitochondrial pellets were washed in 500mL of sucrose buffer 2X (spins done at 10000g for
10min. at 4oC). After the final wash the mitochondrial pellets were resuspended in an
appropriate volume of sucrose buffer and stored at -80oC until further analysis. For protein
analysis mitochondrial supernatants were lysed in an equal volume of sucrose buffer plus 1XPBS
with 2% Triton X-100 plus protease and phosphatase inhibitors.
X. Transfections
Transfections were carried out with the use of FuGENE (Promega). Briefly, plasmid DNA (13µg) was combined with FuGENE reagent at a 1:3 ratio (µg:mL) and incubated in OPTI-MEM
media for 5 minutes prior to adding to cells. For shRNA viral transductions, 293T cells were
transfected via FuGENE with the indicated shRNA vector (1.5µg), pCMV-VSV-G envelope
protein vector (1µg), and pCMV-dR8.2 dvpr packaging plasmid vector (1.5µg). Viral
supernatants were collected after 48H, spun down, and filtered through a 0.45µm filter prior to
adding to cells in the presence of 10µg/mL Polybrene (Millipore). MSCV retroviruses were
similarly packaged in 293T cells following transfection with the appropriate MSCV viral vector
(4µg) and the phoenix helper construct (1µg). Cell transductions were carried out for 24H in the
presence of virus and after 48H puromycin selection (2µg/mL, shRNA experiments) or GFP
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FACS sorting was performed to generate a pure, stable pool of cells expressing the indicated
viral vector.
XI. RNA Extraction and Real-time PCR
RNA was extracted from cells using TRIzol Reagent (ThermoFisher Scientific, #15596026)
according to the manufacturer’s instructions. cDNA’s were constructed using the High Capacity
RNA to cDNA kit (ThermoFisher Scientific, #4387406) from 2µg of purified RNA. cDNA’s
were combined with SYBR green (SensiMix SYBR & Fluorescein Kit, Bioline, QT615) and
forward and reverse primers as outlined in Table 3. Samples were assayed using a CFX96 RealTime PCR Detection System (Bio-Rad, Hercules, CA) and analyzed using the ΔΔCT method.
XII. Mitochondrial Oxygen Consumption
Mitochondrial oxygen consumption in WT MEFs and MDA-231 cells was analyzed using an
XF24 Extracellular Flux Analyzer (Seahorse Bioscience). The day before recording cells were
plated (MEFs: 50,000 cells; MDA-231: 40,000 cells) into an XF24 cell culture microplate
(Seahorse Bioscience). Prior to recording, cells were incubated in unbuffered DMEM, pH 7.4
(93) . Cells were analyzed in the presence or absence of Ruxolitinib (5µM), OSM (12.5ng/mL),
IFNγ (5000U/mL), or DMSO as a control. Oxygen consumption rates for each condition were
normalized to 0 min. basal (unstimulated) oxygen consumption.
XIII. Immunoprecipitation
Immunoprecipitation was carried out as previously described (94) . Mitochondrial or whole cell
extracts were incubated overnight at 4°C with an antibody against STAT3 (SantaCruz, sc-482,
C-20, 1:100 dilution) plus agarose beads (Protein G Sepharose Fast Flow, GE Healthcare, 170618-01) or control IgG plus agarose beads in an IP buffer pH 7.4 (150 mM NaCl, 50mM TrisHCl, 1% Triton, 1 mM EDTA with added protease and phosphatase inhibitor cocktails (Roche,
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Indianapolis, IN). Immunoprecipitates were washed three times with wash buffer (150 mM
NaCl, 50mM Tris-HCl, 1% Triton, protease and phosphatase inhibitor cocktails), and separated
by SDS-PAGE with blotting against the indicated antibodies.
XIV. Microarray
The microarrays were carried out by Dr. Catherine Dumur according to the following protocol.
RNA extraction: Total RNA was extracted and the quality evaluated using a sample processing
method previously established (95) . Total RNA was extracted from WT and STAT3-/- MEFs
with and without OSM stimulation using the MagMAX™-96 for Microarrays Total RNA
Isolation Kit (InvitrogenTM Life Technologies, Carlsbad, CA), in an automated fashion using
the magnetic particle processors MagMAXTM Express. RNA purity was judged by
spectrophotometry at 260, 270, and 280 nm. RNA integrity as well as cDNA and cRNA
synthesis products were assessed by running 1 µL of every sample in RNA 6000 Nano
LabChips® on the 2100 Bioanalyzer (Agilent Technologies, Foster City, CA).
Gene expression microarray analyses: The Affymetrix® protocol utilized for our microarray
analyses has been previously described (95) and was used with the following modifications.
Starting from 500 ng of total RNA, we performed a single-strand cDNA synthesis primed with a
T7- (dT24) oligonucleotide. Second strand cDNA synthesis was performed with the E. coli DNA
Polymerase I, and biotinylation of the cRNA was achieved by in vitro transcription (IVT)
reaction using the GeneChip® 3' IVT Express Kit (Affymetrix, Santa Clara, CA). After a 37°Cincubation for 16 hours, the labeled cRNA was purified using the cRNA cleanup reagents from
the GeneChip® Sample Cleanup Module. As per the Affymetrix® protocol, 10 µg of fragmented
cRNA were hybridized on the GeneChip® Mus Musculus Genome array (Affymetrix Inc., Santa
Clara, CA) for 16 hours at 60 rpm in a 45°C hybridization oven. The GeneChip® Mus Musculus
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Genome array provides a comprehensive coverage of the transcribed Mus Musculus genome by
analyzing the expression level of over 22,500 well-characterized transcripts. The arrays were
washed and stained with streptavidin phycoerythrin (SAPE; Molecular Probes, Eugene, OR) in
the Affymetrix® fluidics workstation. After scanning, the raw intensities for every probe were
stored in electronic files (in .DAT and .CEL formats) by the GeneChip® Operating Software
v1.4 (GCOS) (Affymetrix). Overall quality of each array was assessed by monitoring the 3′/5′
ratios for the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (Gapdh), and the
percentage of “Present” genes (%P). Arrays exhibiting Gapdh 3′/5′ < 3.0 and %P > 40% were
considered good quality arrays.
Statistical analysis: For the microarray data analysis, background correction, normalization, and
estimation of probe set expression summaries was performed using the log-scale robust multiarray analysis (RMA) method (96) . Hierarchical cluster analyses were performed with the
BRB-ArrayTools v3.1.0 (Biometric Research Branch, National Cancer Institute), an Excel add-in
that collates microarray data with sample annotations. In order to identify differentially
expressed genes between the different classes, we performed t-tests for each probe set from
biological replicates in each class. Statistical significance for multivariate analysis to assess
probe set specific false discovery rates (FDR) was performed by estimating the q-values, using
the Bioconductor q-value package (Storey, 2002).
XV. Mass Spectrometry Analysis
Mass Spectrometry Analysis was performed by Weidong Zhou (George Mason University,
Petricoin Lab) on mitochondria from MLS-STAT3Eo transgenic mice subjected to GST-CypD
Pulldown or STAT3 immunoprecipitation. Lysates resolved by SDS-PAGE and stained via
Coomassie were trypsin digested and desalted as done previously (97) . Peptides were analyzed
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by highly sensitive reversed-phase liquid chromatography coupled nanospray tandem mass
spectrometry (LC-MS/MS) using an LTQ-Orbitrap mass spectrometer (Thermo Fisher). Briefly,
the reversed-phase LC column was slurry-packed in-house with 5 µm, 200 Å pore size C18 resin
(Michrom BioResources) in a 100 µm i.d. . 10 cm long piece of fused silica capillary (Polymicro
Technologies) with a laser-pulled tip. After sample injection, the column was washed for 5 min
with mobile phase A (0.1% formic acid), and peptides were eluted using a linear gradient of 0%
mobile phase B (0.1% formic acid, 80% acetonitrile) to 50% B in 160 min at 200 nL/min, then to
100% B in an additional 10 min for proteomics analysis. The LTQ-Orbitrap mass spectrometer
was operated in a data-dependent mode in which each full MS scan (60,000 resolving power)
was followed by eight MS/MS scans where the eight most abundant molecular ions were
dynamically selected and fragmented by collision-induced dissociation (CID) using a normalized
collision energy of 35%. The Dynamic Exclusion Time was 30 s, and the Dynamic Exclusion
Size was 200. The “FT master scan preview mode”, “Charge state screening”, “Monoisotopic
precursor selection”, and “Charge state rejection” were enabled so that only the 1+, 2+, and 3+
ions were selected and fragmented by CID. Tandem mass spectra collected by Xcalibur (version
2.0.2) were searched against the NCBI human protein database using SEQUEST (Bioworks
software from ThermoFisher, version 3.3.1) with full tryptic cleavage constraints, static cysteine
alkylation by iodoacetamide, and variable methionine oxidation.
XVI. Pulldown Assays
Pulldown assays were performed as previously described (48) . Briefly, recombinant beadbound GST-CypD or GST alone were blocked in H-buffer (20mM HEPES pH 7.7, 1mg/mL
BSA, 75mM KCl, 0.1mM EDTA, 2.5mM MgCl2, 0.05% NP-40, 1mM DTT). 250µg of
mitochondrial or whole cell extracts (lysed as described above) were incubated with 20µg of
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bead bound GST-CypD or GST alone and incubated overnight at 4oC. Beads were pelleted and
washed in H-buffer and bound proteins were analyzed by immunoblotting.
XVII. Proximity Ligation Assay
Proximity Ligation Assays were performed according to manufacturer’s instructions (Duolink,
Sigma). For PLA cells were fixed in 4% paraformaldehyde for 15 min at RT and then rinsed 3x
for 1min. with 1XPBS. Cells were permeabilized in ice cold methanol for 10min. at -20 oC after
which cells were washed with 1XPBS for 5min. at RT. Cells were blocked in 1XPBS with
1%BSA and 0.05% Tween-20 for 30 minutes at RT. The STAT3 antibody was diluted 1:1000
and the CypD Antibody was diluted 1:500 in 1XPBS with 1%BSA and 0.05% Tween-20 and
added to the cells for incubation overnight at 4 oC. Oligonucleotide PLA probes and subsequent
ligation were carried out as directed by the manufacturer. Cells were mounted with ProLong
Gold Antifade (ThermoFisher Scientific, P36930) and visualized using a Zeiss 700 upright
confocal microscope with the recommended excitation and emission filters.
XVIII. Liver Mitochondrial Assays
8-12 week old male CD-1 mice (Charles River Laboratories) were tail vein injected with
500µg/kg recombinant murine IL-6 (Peprotech) and sacrificed at the indicated times. Livers
were harvested from mice and washed with ice cold PBS. The livers were minced and
homogenized in 10mL MSM (220mM Mannitol, 70mM Sucrose, 5mM MOPS) on ice. A
homogenate fraction was collected for each sample and solubilized as described above.
Homogenized tissues were then centrifuged at 500xg for 10 minutes at 4°C to remove cell
debris. The supernatants were centrifuged at 3700xg for 10 minutes at 4°C to pellet
mitochondria. Mitochondria were re-suspended in 5mL of ice cold MSM-EDTA (MSM Buffer
plus 2mM EDTA) and spun at 3700xg for 10 minutes at 4°C. Supernatants were discarded and
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the mitochondria were re-suspended in 2.5mL of MSM-EDTA buffer and spun down at 3700xg
for 10 minutes at 4°C (75) . Mitochondria in MSM-EDTA buffer were lysed via the addition of
an equal volume of 2% Triton X-100 in 1X PBS with protease and phosphatase inhibitor
cocktails and analyzed via immunoblotting.
XIX. Calcein/CoCl2 Assays
Mitochondrial Permeability Transition was assessed using the MitoProbe Transition Pore Assay
Kit (ThermoFisher Scientific, #M34153) as previously described (48) . Cells were loaded with
1µM Calcein-AM and 1mM CoCl2 in Hank’s Balanced Salt Solution (HBSS) with calcium
modified to include 10mM HEPES, 2mM L-glutamine, and 100µM succinate. Cells were
labeled for 15min. at 37oC in the dark in a humidified cell culture chamber. Cells were washed
in warm modified HBSS buffer and treated as indicated with analysis via fluorescence activated
cell sorting (FACS, BD Canto II) or live cell imaging (Zeiss Cell Observer Spinning Disc
confocal microscope, heated chamber, 63x oil immersion).
XX. Mitochondrial Membrane Potential
Mitochondrial membrane potential was assessed by monitoring the uptake of the cationic dye
TMRE (tetramethylrhodamine, ethyl ester, perchlorate, 100nM added to culture media) by FACS
(BD, Canto II). Alternatively, it was measured by the ratio of intensity of red:green fluorescence
of the cationic dye JC-1 (ThermoFisher Scientific, #T3168). Cells were loaded with 5µM JC-1
in cell culture media and incubated for 15min. at 37oC in a humidified cell culture chamber with
5% CO2. Cells were washed and dye was visualized using a Zeiss LSM 710 inverted confocal
microscope with excitation by 488nm and 561nm lasers. Mean intensities in the red and green
channel were evaluated and serve as a measure of the polarization state of the mitochondria
independent of mitochondrial number, size, or shape.
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XXI. Mitochondrial Superoxide Production
Production of mitochondrial superoxide was measured as previously described (33) . MitoSOX
(ThermoFisher Scientific #M36008), a mitochondrial superoxide indicator, was loaded onto cells
(5µM) in HBSS/Ca2+ media for 30min. MitoSOX was analyzed via FACS (BD Canto II) with
excitation at 488nm and data collection at the Forward Side Scatter (FSC), side scatter (SSC)
585/42nm (FL2) channel. For cell imaging cells were co-stained with DAPI and mounted in
warm HBSS/Ca2+ buffer with imaging performed on a Zeiss LSM 710 inverted confocal
microscopre (Excitation 405nm and 561nm).
XXII. Calcium Retention Capacity (CRC) Assays
To further assess MPTP susceptibility, calcium retention capacity (CRC) assays were performed
on whole cells as previously described (98, 99) . Briefly, cells were washed in Ca2+ free PBS
and an equal amount of cells 10x106/mL were resuspended in swelling buffer (120mM KCl,
10mM Tris-HCl, 5mM MOPS, 5mM Na2HPO4, 10mM glutamate, and 2mM malate). Cell
suspensions were permeabilized with 40µg/mL digitonin and all measurements were done in the
presence of the SERCA pump inhibitor thapsigargin to prevent ER Ca2+ uptake. To assess CRC,
cell suspensions were continuously stirred and loaded with 1µM of the Ca2+ indicator Calcium
Green-5N. 10µM Ca2+ pulses were added to the cells (1/minute) until MPTP opening was
observed as an increase in fluorescence detected using an LS55 spectrophotometer (Perkin
Elmer).
XXIII. Ex Vivo Model of Stop Flow-simulated Ischemia
Hearts from 8-10 week old transgenic MLS-STAT3Eo mice were excised and subjected to an exvivo ischemia model (11) . Hearts from transgenic mice were placed in 0.9% NaCl in sterile
H2O and placed on ice or at 37oC in a digitally controlled tube shaker set to 1,400RPM to
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simulate ischemia. Mitochondria was then isolated from hearts by finely mincing heart tissue in
Chappell-Perry Buffer (CP Buffer, pH 7.4, 100 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM
MgSO4·7H2O, 1 mM ATP) and then digested by the addition of 5mg/g wet weight trypsin for
15min. on ice with gentle agitation. 3mL’s of CP buffer with 5% BSA was added to quench the
excess trypsin and terminate the reaction at which point the tissue was homogenized via ten
strokes with a digital steady-stirring tight Teflon pestle and glass tube set to 4000RPM.
Homogenates were spun down at 500g for 10min. at 4oC and the supernatant containing
mitochondria were transferred to a new tube and spun at 3000g for 10min. at 4oC. The
mitochondrial pellet was washed with 2 ml of KME buffer, pH 7.4 (100 mM KCl, 50 mM
MOPS, 0.5 mM EGTA) and spun at 3000g for 10min. at 4oC. Mitochondria were re-suspended
in KME buffer and stored at -80oC until lysis and subsequent analysis via immunoblotting and/or
GST-CypD pulldown.
XXIV. Cell Free System for Studying mitoSTAT3-CypD Interactions
Mitochondria or whole cell extracts were prepared as above, but importantly in the absence of
protease or phosphatase inhibitors. Lysates were incubated on ice or at 30oC for 30 minutes in
1X NEBuffer for Protein Metallophosphatases (50mM HEPES, 10mM NaCl, 1mM MnCl2, 2mM
DTT, 0.01% Brij 35, pH 7.5). Following incubation, extracts were subjected to GST-CypD
pulldown as described.
XXV. Statistical Analysis
Results are presented as the mean ± SEM.	
 Statistical Analyses were performed using GraphPad
Prism 7 with the indicated statistical test and corresponding p-values as mentioned in the figure
legends. N=2-3 for experiments, unless otherwise indicated.
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Figure 6: Schematic of Isolation of Pure Mitochondria. Reprinted from (92) , copyright
license number 3852200514347.
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Table 3: Primer sequences used for qPCR analysis.

Primer Name
mBNIP
mNfyb
mATF3
mATF4
mHOX1
mNRF2
mND6
mCOXII
mCytb
mATPase6

Sequence
Forward: TCCTGGGTAGAACTGCACTTC
Reverse: GCTGGGCATCCAACAGTATTT
Forward: GCCTCCCAGCTAGGGATTTC
Reverse: TTCCTGTTTGAGGTATGGCATTT
Forward: GAGGATTTTGCTAACCTGACACC
Reverse: TTGACGGTAACTGACTCCAGC
Forward: CTCTTGACCACGTTGGATGAC
Reverse: CAACTTCACTGCCTAGCTCTAAA
Forward: AAGCCGAGAATGCTGAGTTCA
Reverse: GCCGTGTAGATATGGTACAAGGA
Forward: CTGAACTCCTGGACGGGACTA
Reverse: CGGTGGGTCTCCGTAAATGG
Forward: TTGGTTGTGTTGGGTTAGCA
Reverse: ACCAATCTCCCAAACCATCA
Forward: AAACTGATGCCATCCCAGGC
Reverse: AGGTTAACGCTCTTAGCTTCATAGTG
Forward: CCCAACAGGATTAAACTCAGATGCAG
Reverse: GGATTGAGCGTAGAATGGCGTATG
Forward: GGATTCCCAATCGTTGTAGCCA
Reverse: AAGGCCTAGGAGATTTGTTGATCC
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RESULTS

Abstract
Since its discovery more than twenty years ago, Signal Transducer and Activator of
Transcription 3 (STAT3) has been tied to a diverse set of physiological and pathological
functions encompassing development, aging, and everything in between. Classically activated
by the JAK family of receptor associated tyrosine kinases, the pleotropic actions of STAT3 as a
nuclear transcription factor have been thoroughly characterized. However, in addition to
regulating nuclear transcription, a small pool of STAT3 resides in the mitochondria where it
serves as a sensor and signaling hub for a number of metabolic stressors including reactive
oxygen species (ROS). Mitochondrial-localized STAT3 (mitoSTAT3) largely exerts its effects
through regulation of the activity of the electron transport chain (ETC), though it has been tied to
a number of mitochondrial processes. In contrast to cytokine-induced import of STAT3 into the
nucleus, it has been assumed that levels of STAT3 in the mitochondria are static.
We now show that various stimuli, including oxidative stress and cytokines, trigger a
novel signaling cascade that results in a rapid loss of mitoSTAT3. Recovery of mitoSTAT3,
with time, is dependent upon S727 phosphorylation of STAT3 and new protein synthesis. Under
these conditions mitoSTAT3 also becomes competent to bind to Cyclophilin D (CypD).
Binding of STAT3 to CypD is surprisingly mediated by the N-terminus of STAT3, thereby
defining a site outside of S727 that may be important in regulating mitochondrial STAT3. These
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results outline a previously unappreciated role for mitoSTAT3 in sensing external stimuli and
provide evidence of a novel mitochondrial pathway.
Though the functional importance of mitoSTAT3 has been well established, the impact
of this signaling pathway is still unclear. Emerging data would suggest that perhaps changes in
mitoSTAT3 levels and its subsequent association with CypD is a key step in mitochondrial
quality control and potentially, extra-mitochondrial signaling. What is clear is that the regulation
of mitochondrial STAT3 levels by various stimuli provides evidence for a novel signaling
pathway that links mitochondrial responses with those of the cell. This would be advantageous
in that it would unify responses in distinct subcellular locations to coordinately regulate cell
homeostasis.
Introduction
Signal Transducer and Activator of Transcription 3 (STAT3), a member of the STAT
family of nuclear transcription factors, plays a key role in the regulation of a diverse set of
physiological processes. Ideally situated as a molecular link between cellular inputs and nuclear
gene regulation, STAT3 also features prominently in most pathological conditions. For years,
the intricacies of this signaling network have been teased out in order to better appreciate the
mechanisms behind STAT3’s regulation and downstream targets (100) . The hope being that
this information could be effectively used to modulate STAT3 and its effectors for the purposes
of advancing health and mitigating disease. With the discovery of a distinct pool of STAT3 that
resides in the mitochondria (1, 2) , a new door has opened in our understanding of the
importance of STAT3 in controlling cellular homeostasis.
The functional significance of mitochondrial STAT3 (mitoSTAT3) has been extensively
explored. It has been linked to control of the electron transport chain (ETC) and ATP
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production, mitochondrial encoded RNA regulation, modulation of reactive oxygen species
generation, Ras transformation and cellular growth, and protection in ischemia-reperfusion
injuries through regulation of the mitochondrial permeability transition pore, amongst others
(101) . Most reports attribute phosphorylation of STAT3 at S727 as being key for its
mitochondrial role with the MEK-ERK signaling axis potentially being an important player (7,
102) . However, the signaling pathways that control mitoSTAT3 largely still remain to be
elucidated. This is especially important when considering that most studies looking to target
STAT3 for therapeutic purposes have neglected its mitochondrial role, which could partly
explain the absence of a successful clinical STAT3 inhibitor to this point (30, 103) . In order to
more effectively study and target mitoSTAT3 we sought to examine its regulation at the
signaling level.
We now report that mitoSTAT3 is dynamically regulated by a number of cellular inputs,
including oxidative stress and cytokines. Under these conditions mitoSTAT3 levels initially
decrease, which is likely mediated by protease driven degradation. This is followed by a reequilibration of STAT3 at the mitochondria that is dependent upon S727 phosphorylation.
During this recovery phase, mitoSTAT3 binds to Cyclophilin D (CypD), with the latter likely
playing a chaperone role in stabilizing the mitochondrial STAT3 pool. Interestingly, the Nterminus of mitoSTAT3 appears to be necessary for its association with CypD, thereby pointing
to a site outside of S727 in STAT3 that is important for its mitochondrial function. These results
provide insight into a novel-signaling pathway that controls mitoSTAT3 and may provide a
means to better characterize and target the mitochondrial pool of STAT3.
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I. Dynamic Regulation of Mitochondrial STAT3 and Its Association with CypD
A. Rapid Loss of Mitochondrial STAT3 following an Oxidative Stress Insult
MitoSTAT3 has been previously shown to be an important player in limiting
mitochondrial and cellular ROS production (11, 17, 18, 33, 104) . STAT3 is also known to be
post-translationally modified by oxidation that in turn regulates its function (65, 105) and ROS
may be an important cue for controlling mitoSTAT3 levels (106) . Because of this we sought to
assess how mitochondrial STAT3 is regulated following an oxidative insult. Surprisingly, we
observed an initial loss of STAT3 from the mitochondria in WT MEFs or 4T1 cells treated with
hydrogen peroxide that recovers with time (Figure 7A). This was not observed in cytosolic
fractions from WT MEFs or 4T1 cells (Figure 7B) likely suggesting against global degradation
of the protein. Under these conditions we also observe phosphorylation of STAT3 at both Y705
and S727 (Figure 8A and 8B) with the expected increase in nuclear levels of STAT3 (Figure
8C). The loss of mitoSTAT3 upon treatment with H2O2 is concentration dependent and also
seems to coincide with activation of MAPK pathways (Figure 7C). Interestingly, though we
noted potent S727 phosphorylation of mitoSTAT3 following H2O2 treatment (Figure 8D)
mutation of either S727 or Y705 did not affect the decrease we see in mitoSTAT3 levels (Figure
8F).
The kinetics of this pathway were much more rapid than initially anticipated as treatment
with H2O2 for only 7.5 min. sufficiently drives the loss of mitoSTAT3 with recovery starting to
occur by 30 min. (Figure 7D, upper panel). The loss we observe with mitoSTAT3 appears to
be specific as mitochondrial STAT1 (mitoSTAT1) levels are unchanged following an oxidative
insult (Figure 7D, lower panel). Probing mitochondrial extracts with a diverse set of STAT3
antibodies targeted to both the N- and C-terminus all show the same loss of mitoSTAT3 upon
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H2O2 treatment making it unlikely that STAT3 is modified such that it is no longer
immunoreactive (Figure 8G). Similar treatment of MDA-231 or SK-BR3 human breast cancer
cell lines with H2O2 also drives a loss of mitoSTAT3 (Figure 7E). Mitochondria isolated from
WI-38 human lung fibroblasts treated with H2O2 and immediately placed in sample buffer
containing SDS and β-mercaptoethanol also display a loss of mitoSTAT3 (Figure 7F). This
result would suggest that it is unlikely that mitoSTAT3 is going into an insoluble fraction in the
mitochondria and points to a true loss of the protein from this organelle. Also, it appears from
these experiments and others (Figure 8E, data not shown) that the exact timing of the loss and
recovery is highly cell dependent though we observe this phenomenon in most cell lines we have
investigated.
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Figure 7: Oxidative Stress Triggers a Loss of Mitochondrial STAT3. WT MEFs or 4T1 cells
were treated with 1mM H2O2 for the indicated times and mitochondrial (A) or cytosolic (B)
extracts were probed for STAT3. Quantification of mitoSTAT3 as compared to a loading
control is depicted in (A). *p≤0.05 (versus control) , One-way ANOVA, Dunnett’s multiple
comparisons test; #p≤0.05 (versus control) , One-Way ANOVA, Dunnett’s multiple comparisons
test. (C) WT MEFs were treated with increasing concentrations of H2O2 and assessed for
mitoSTAT3 and pY705 STAT3 in the cytosol (Tubulin: cytosolic loading control; CypD:
mitochondrial loading control). (D) Isolated mitochondria from WT MEFs treated for the
indicated times with H2O2 were immunoblotted for mitoSTAT3 or mitoSTAT1 and quantified.
*p≤0.05, Student’s T-test. (E) MDA-231 [ER-/PR-/HER2-] and SK-BR3 [ER-/PR-/HER2+]
human breast cancer cells were treated for the indicated times with H2O2 and immunoblotted for
STAT3. (F) WI-138 human lung fibroblasts were treated with H2O2 and purified mitochondria
were combined with an equal volume of sample buffer containing SDS and β-mercaptoethanol to
ensure that the decrease in mitoSTAT3 that we observe was not due to STAT3 entering an
insoluble fraction.
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Figure 8: S727 and Y705 of STAT3 are Not Required for H2O2 Induced mitoSTAT3 Loss.
4T1 or WT MEF cytosolic extracts were probed for pY705 (A) or pS727 (B) STAT3. (C) 4T1
nuclear extracts were immunoblotted for STAT3 to confirm the expected increase in nuclear
STAT3 levels after stimulation. (D) Mitochondrial lysates were probed for pS727 STAT3 and
total mitoSTAT3 levels and quantified via densitometry analysis. *p <0.03, Student’s T-test. (E)
Mitochondria were isolated from HeLa cells treated for the indicated times with H2O2 and lysates
were resolved by SDS-PAGE and blotted for STAT3. (F) STAT3-/- MEFs were reconstituted
with WT STAT3 (STAT3a) or S727 and Y705 mutants. Mitochondrial extracts both before and
after H2O2 were analyzed for STAT3 expression. Cytosolic levels of STAT3 Y705 and S727
mutants are shown as a control. (G) A varied panel of STAT3 antibodies all show a similar
reduction in mitoSTAT3 levels after H2O2 treatment. D3Z2G (Cell Signaling, rabbit
monoclonal, C-terminus), 79D7 (Cell signaling, rabbit monoclonal, C-terminus), 124H6 (Cell
Signaling, mouse monoclonal, C-terminus), N-term Ab (BD Biosciences, mouse monoclonal, Nterminus).
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B. Loss and Recovery of MitoSTAT3 with Cytokine Administration
As STAT3 is classically activated by IL-6 family cytokines, which bind to their
respective receptor and transduce signals via gp130, we next wanted to investigate whether or
not typical STAT3 stimuli could produce similar effects on mitoSTAT3. Treatment of MEFs
with the IL-6 family member Oncostatin M (OSM) drives a loss of mitoSTAT3 within minutes
that again recovers with time (Figure 9A). Similar results were obtained when cells were treated
with IL-6 with no apparent effects on cytosolic STAT3 levels (Figure 9B). As had been
observed with H2O2 administration, the kinetics of the loss and recovery of mitoSTAT3 with
cytokine treatment is highly cell dependent, though still at work in mouse and human cell lines
alike (Figure 9C, Figure 10A). Prior reports have indicated that longer-term treatment of cells
with cytokines (15) or growth factors (31, 102, 107) drives an increase in mitochondrial
STAT3 levels. This is also re-capitulated in our system as MEFs stimulated with OSM for 2H
display an increase in mitoSTAT3 pointing to differential regulation of mitoSTAT3 in the acute
versus chronic setting (Figure 10B, 2H, lane 5). Likewise, treatment of cells with buthionine
sulfoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase that will deplete intracellular
glutathione and promote a more chronic oxidative stress condition, also leads to an increase in
mitoSTAT3 with time (Figure 10C).
The above results implicate that signals originating from the plasma membrane can be
transduced to the level of the mitochondria. To further demonstrate this we took advantage of
cell lines containing chimeric receptors expressing the extracellular domain of granulocyte
colony stimulating factor (GCSF) coupled intracellularly to gp130 (108) . Treatment with GCSF
produced the same loss of mitoSTAT3 and subsequent recovery (Figure 9D). This
mitochondrial signaling pathway is not exclusively driven by gp130 coupled stimuli though as
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interferon β (IFNβ), a type I interferon known to activate STAT3, also causes a loss of
mitoSTAT3 (Figure 9E, Figure 10D). Importantly, not all stimuli activate this cascade as
interferon γ (IFNγ, Figure 10E) and epidermal growth factor (EGF, Figure 10F) failed to drive a
significant loss of mitoSTAT3. Though crude mitochondria used for these studies were
trypsinized to minimize contamination from the cytosol and other organelles, we further purified
mitochondria over a percoll gradient (92) in order to separate the mitochondria from the tightly
linked mitochondrial associated membranes (MAM). Under these conditions, mitoSTAT3 still
decreases with OSM treatment (Figure 9F, P-Mito) confirming a loss of STAT3 specifically
from the mitochondrial fraction. This pathway is also likely functionally relevant in vivo, but
may be difficult to fully explore as mice injected with saline alone display a robust decrease in
mitoSTAT3 levels, likely due to stress pathways induced by injecting the animal (Figure 10G).
Together these results show that mitoSTAT3 is dynamically regulated by a number of stressors.
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Figure 9: Cytokine Treatment Also Induces mitoSTAT3 Loss and Recovery.
(A) OSM and (B) IL-6 drive a loss of mitoSTAT3 in WT MEFs in as little as a few minutes that
is comparable to H2O2 treatment with a more rapid recovery. Cytosolic extracts probed for
pY705 STAT3 are shown to confirm proper cell activation. (C) Mitochondria from 4T1 cells
treated with OSM (upper panel) or MDA-231 cells treated with IL-6 (bottom panel) were probed
for STAT3. (D) Rat hepatoma cell lines expressing the chimeric GCSF-gp130 receptor were
stimulated with recombinant human GCSF and immunoblotted for STAT3 in the mitochondrial
fraction or pY705 STAT3 in the cytosolic fraction. (E) IFNβ treatment of MDA-231 cells also
shows effects on mitoSTAT3 (top panel) with the appropriate activation seen in the cytosolic
fraction. (F) Purified mitochondria (P-Mito) supports the data from crude mitochondrial isolates
on the loss and recovery of mitoSTAT3. Control or OSM stimulated WT MEFs were
fractionated into cytosolic (cyto), ER (endoplasmic reticulum), crude mitochondria (C-mito),
pure mitochondria (P-mito), and a mitochondrial associated membrane fraction (MAM) and
blotted against a total homogenate fraction (Homog.). Calreticulin (ER and MAM marker),
Tubulin (cytosolic marker), NDUFA9 (mitochondrial marker), Histone H3 (nuclear marker), and
STAT3 levels are shown.
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Figure 10: Selectivity of the mitoSTAT3 Signaling Pathway and Relevance In Vivo
(A) BT474 [ER-/PR-/HER2+] human breast cancer cells treated with OSM were probed for
mitoSTAT3. (B) Mitochondria from WT MEFs treated with OSM over the indicated times were
isolated and extracts were run for STAT3 levels. Note the increase in mitoSTAT3 after 2H of
treatment (lane 5). (C) WT MEFs were treated with Buthionine Sulfoximine (BSO) and
mitochondrial extracts were immunoblotted for mitoSTAT3. (D) WT MEFs were treated for the
indicated times with IFNβ and mitochondrial lysates were run to confirm results from IFNβ
treated MDA-231 cells (Figure 9E). Cells treated with IFNγ (E) or EGF (F) do not show a loss
of mitochondrial STAT3 demonstrating specificity of the system. (G) 8-12 week old CD1 male
mice were tail vein injected with either PBS or IL-6 (500µg/kg) and liver mitochondrial (left
panel) or cytosolic fractions (right panel) were immunoblotted for STAT3 and pY705 STAT3
respectively. A non-injected control liver extract was included (Lane 1) to demonstrate the
change in baseline with PBS injection alone.
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C. JAK Blockade Attenuates mitoSTAT3 Loss Following Cytokine Treatment
As the Jak family of receptor associated tyrosine kinases drives downstream signaling
events from IL-6 family cytokines and interferons, we next tested whether or not inhibition of
Jak kinase activity prevented the loss of mitoSTAT3. Pre-treatment of MEFs with the pan-Jak
inhibitor Ruxolitinib potently suppressed the observed loss of mitoSTAT3 with both OSM
(Figure 11A) and IL-6 (Figure 12A) treatment. Not surprisingly, Ruxolitinib was unable to
block the effects seen on mitoSTAT3 with H2O2 (Figure 11B), which can likely bypass receptor
mediated activation and act on a number of other downstream signaling cascades. These results
were mirrored in MDA-231 cells pre-incubated with Ruxolitinib and then subjected to either
OSM or H2O2 treatment (Figure 11C). Inhibition of STAT3 directly via its SH2 domain with
the small molecule cryptotanshinone also did not suppress OSM induced mitoSTAT3 loss
(Figure 12B). This is consistent though with prior reports that demonstrate that the SH2 domain
is dispensable for mitoSTAT3’s actions (1, 2, 33) .
To get a sense as to what the downstream mediators were that transduce the signal from
the receptor to the mitochondria, we evaluated differences between OSM and H2O2 treatment of
cells. Notably, H2O2 produces a robust increase in mitochondrial ROS production that is not
seen with OSM (Figure 11D). Considering that STAT3 can be regulated by oxidative
modifications (66) and a number of signaling pathways can be activated independently of
upstream events in the presence of ROS (109) , we tested whether antioxidants could block the
loss of mitoSTAT3 with H2O2 treatment. The mitochondrial targeted antioxidant mitoTEMPO
(110) was unable to suppress the H2O2 induced decrease in mitoSTAT3 (Figure 11E) likely
ruling out an oxidative driven program.
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In further evaluating the signaling pathway driving mitoSTAT3 loss it was noted that
Ruxolitinib was able to inhibit OSM induced ERK activation, but not ERK activation stimulated
by H2O2. STAT3, and in particular mitochondrial STAT3, has been linked to regulation by the
MEK-ERK pathway (7) , and mitoSTAT3 levels may be controlled by this cascade (102) .
MEK blockade with the inhibitor PD0325901 completely inhibited H2O2 mediated activation of
ERK, but did prevent mitoSTAT3 loss (10’ H2O2 treatment) or its initial recovery (30’ H2O2
treatment) (Figure 11F). This suggests that the MEK-ERK pathway is dispensable for these
actions on mitoSTAT3, or alternatively, that there is compensation from another signaling
molecule. However, pre-treatment with the broad-spectrum kinase inhibitor staurosporine was
unable to block mitoSTAT3 loss (Figure 12C), nor was the protein kinase inhibitor H7
dihydrochloride (Figure 12C). The latter is a known protein kinase A (PKA) and protein kinase
C (PKC) inhibitor, both of which have been implicated in mitoSTAT3 biology (107, 111) . A
number of other signaling cascades have been shown to converge on STAT3 including p38,
PI3K/Akt, JNK, and mTOR (112) but targeting each of these pathways individually was not
sufficient to inhibit mitoSTAT3 loss (Figures 12D-G). These results point to the idea that
multiple signaling events may affect mitoSTAT3 making complete delineation of the
downstream regulation of this pathway challenging.
To date the only kinase inhibitor that has been able to prevent mitoSTAT3 loss with H2O2
treatment is the fungal metabolite wortmannin (Figure 13A), which irreversibly inhibits PI3K
but with potent off target effects. The effect of wortmannin here is likely driven through an
action of the compound outside of its PI3K inhibition as the more specific PI3K inhibitor
LY294002 is unable to re-capitulate these results (Figure 13B). Wortmannin has been
implicated in also targeting ataxia telangiectasia mutated (ATM) kinase, as well as off-target
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effects on ribosomal s6 kinase (RSK) and autophagy regulation. Inhibition of each of these
cascades individually did not block mitoSTAT3 loss (Figures 13E-G) nor did simultaneous
inhibition of both PI3K and MEK mediated signaling events (Figure 13F). Of note, it appears
that wortmannin reduces basal mitoSTAT3 levels (roughly 50%, Figure 13A), which may lead
to a dampening of this signaling pathway. Though we observe the loss of mitoSTAT3 in most
cell lines studied, those with low basal levels of mitoSTAT3 fail to show any further reduction in
mitochondrial levels of STAT3 (data not shown). This points to a tight regulation of
mitoSTAT3 and cell line and context dependent stimulation of the pathway. Curiously,
wortmannin also blocked the interaction of STAT3 with Cyclophilin D (CypD) (Figure 13C,
Figure 13D) suggesting a potential connection between the loss and recovery of mitoSTAT3 and
binding to CypD, which will be discussed in more detail below.
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Figure 11: JAK Blockade Prevents mitoSTAT3 Loss Upon Cytokine Treatment
MEFs were incubated with or without the JAK inhibitor ruxolitinib prior to the addition of OSM
(A) or H2O2 (B), and mitochondrial and cytosolic extracts were immunoblotted for STAT3 or
pY705 STAT3 respectively. (C) Mitochondria were isolated from MDA231 breast cancer cells
treated with ruxolitinib prior to the addition of OSM or H2O2 for the indicated times. *Courtesy
of MoonJung Hyun. (D) Mitochondrial superoxide production was assayed via flow cytometry
analysis using the MitoSOX dye in WT MEFs treated for 30’ with either OSM or H2O2.
*p<0.001, Student’s T-test. (E) Pre-treatment of cells with the mitochondrial restricted antioxidant mitoTEMPO does not attenuate mitoSTAT3 loss as assessed by western blot. (F) WT
MEFs were pre-treated with the MEK inhibitor PD0325901 followed by H2O2 treatment for the
indicated times and isolated mitochondria were subjected to SDS-PAGE and immunoblotted for
STAT3, pERK1/2, and NDUFA9 (loading control).
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Figure 12: Inhibition of Relevant Kinase Pathways does not Affect Stimulation Induced
Decreases in mitoSTAT3. (A) WT MEFs were treated with IL-6 either in the presence or
absence of Ruxolitinib and mitochondrial and cytosolic extracts were evaluated via western
blotting. (B) MDA-231 cells pre-treated with the STAT3 inhibitor cryptotanshinone still display
OSM driven mitoSTAT3 loss. Mitochondrial and cytosolic extracts are depicted. (C) WT MEFs
were incubated with Staurosporine or H7 Dihydrochloride prior to H2O2 treatment and
mitochondrial (left panel) and cytosolic (right panel) fractions were immunoblotted for relevant
proteins. Inhibition of a number of kinase pathways including p38 MAPK (D, SB203580), PI3K
(E, LY294002), mTOR (F, Torin 1), or JNK (G, SP600125) did not alter the observed loss of
mitoSTAT3 following either OSM or H2O2 treatment (representative western blots).
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Figure 13: Wortmannin Inhibits H2O2 Mediated changes in mitoSTAT3 via an Off-target
Effect. Mitochondrial extracts from WT MEFs treated with H2O2 that had either been vehicle
pre-treated or treated with wortmannin (A) or LY294002 (B) were blotted for STAT3, pAkt,
pERK1/2, and NDUFA9 (loading control). (C) Mitochondrial lysates from (A) were subjected to
a GST-CypD Pulldown and western blotted for STAT3 and GRIM19 (control). (D) GST-CypD
pulldown (top panel) of whole cell extract samples from cells pre-treated with wortmannin or
LY294002 followed by H2O2 treatment were immunoblotted for STAT3 (Input, bottom panel).
Blockade of common off-target effects of wortmannin including ATM inhibition (E, KU60019), autophagy inhibition (F, BafilomycinA), or p90 RSK inhibition (G, BI-D1870) do not
re-captiulate what is seen with wormannin treatment. (F) Simultaneous inhibition in MDA-231
cells of MEK/ERK (PD0325901) and PI3K/Akt (LY294002) pathways, both of which are shown
to regulate STAT3 signaling, does not prevent loss of mitoSTAT3 upon OSM treatment as
assessed by western blotting.
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D. Recovery of mitoSTAT3 After Stimulation is Dependent on New Protein Synthesis
Since we were unable to definitively link a kinase pathway with the decreases we observe
in mitoSTAT3 following a stimulus, we investigated the potential contribution of proteolysis as a
mechanism behind mitoSTAT3 regulation. STAT3 has been previously shown to be cleaved by
proteases such as caspases (113) and calpains (114) , the latter known to be active in the
mitochondria (115) . However, treatment with the calpain inhibitor MDL-28170 did not block
H2O2 induced mitoSTAT3 loss (Figure 14A). Within the mitochondria protein degradation is
driven by two key serine proteases, Lon protease and ClpP Protease, which are essential for
mitochondrial protein quality control (116) . We utilized the synthetic triterpenoid CDDO-Me
to target Lon protease, which has been shown to inhibit its proteolytic activity in a number of cell
models (117, 118) . Pre-treatement with CDDO-Me also did not block the loss of mitoSTAT3
following an oxidative stress insult (Figure 14B). The general proteasome inhibitor MG132,
which also inhibits Lon protease and attenuates proteasome mediated outer mitochondrial
membrane degradation (119) , failed to block the decrease in mitoSTAT3 seen with either OSM
or H2O2 (Figure 15A). This led us to examine how the absence of ClpP protease affected
mitoSTAT3 regulation.
Primary ClpP+/+ and ClpP-/- MEFs were treated with OSM and H2O2 in the acute setting
and probed for mitoSTAT3. However, in the absence of ClpP, H2O2 and OSM still induced a
loss of mitoSTAT3 (Figure 15B). This was confirmed in MDA-231 cells where ClpP was
depleted via shRNA targeting (Figure 14C). Though we have been unable to demonstrate an
individual protease function in regulating mitoSTAT3 levels it is probable that degradation is the
most likely culprit. STAT3-/- MEFs expressing a mitochondrial targeted STAT3 treated with
H2O2 show the same loss of STAT3 in whole cell extract samples as from mitochondrial
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fractions likely suggesting loss of the protein (Figure 14D). As such, we asked whether or not
protein synthesis was needed to drive full recovery of mitoSTAT3 levels. Indeed, inhibition of
protein synthesis reduced the recovery of mitoSTAT3 following either OSM or H2O2 treatment
in MDA-231 cells (Figures 15C and D). Similar results were obtained from H2O2 treated WT
MEFs incubated with cycloheximide (Figure 14D). S727 phosphorylation of STAT3 has been
previously shown to be important for STAT3’s trafficking to the mitochondria and may at least
in part regulate its import (6) . As such, we speculated that mutation of serine 727 to alanine
would also negatively affect the re-equilibration of mitoSTAT3 following its loss from the
mitochondria. STAT3-/- MEFs expressing S727A STAT3 did not recover to the same extent as
STAT3-/- MEFs expressing STAT3α after 30’ OSM treatment (Figures 15E and F). These
results provide a mechanistic insight into the regulation of mitoSTAT3 and provide a system
through which the signaling pathways controlling STAT3 and its mitochondrial localization can
be more effectively explored.
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Figure 14: Inhibition of mitoProteases Does Not Affect Proteolysis of mitoSTAT3. (A) Cells
pretreated with the calpain inhibitor MDL-28170 were treated with H2O2 and mitochondrial
extracts were probed for STAT3. (B) Cytosolic (bottom panel) and mitochondrial lysates (top
panel) from Lon protease inhibitor treated (CDDO-Me) WT MEFs were interrogated via western
blotting. (C) MDA-231 cells stably expressing a non-targeting shRNA (shScr) or those
containing a ClpP protease directed shRNA (shClpP) were treated with OSM or H2O2.
Mitochondria and cytosol were probed for STAT3, Actin (cytosolic marker), ClpP
(mitochondrial marker), and CypD (mitochondrial marker). (D) STAT3-/- MEFs were
engineered to stably express mitochondrial targeted STAT3 (MLS-STAT3) and subjected to
H2O2 treatment. Whole cell extract (WCE) and mitochondria were western blotted for STAT3 or
the respective loading control. Equivalent loss of mitoSTAT3 from WCE and mitochondrial
fractions suggests proteolysis of mitoSTAT3. (E) WT MEFs were treated with cycloheximide
for 2H prior to H2O2 stimulation and isolated mitochondrial extracts were immunoblotted. Note
absence of full recovery in mitoSTAT3 levels at 2H (lane 6) in the presence of cycloheximide.
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Figure 15: Recovery of mitoSTAT3 is Dependent on New Protein Synthesis and S727
Phosphorylation of STAT3. (A) Mitochondria from MDA-231 cells were pre-treated for 4H
with vehicle or the general proteasome inhibitor MG132 and treated with OSM or H2O2 and
evaluated for changes in mitoSTAT3 levels. Cytosolic extracts from MG132 treated cells were
probed for Ubiquitin (Ub) to confirm the effect of MG132. (B) ClpP+/+ or ClpP-/- MEFs were
treated with either OSM or H2O2 and mitochondrial and cytosolic fractions were probed for
STAT3, Actin (cytosolic loading control and marker), ClpP, and CypD (mitochondrial loading
control and marker). (C) Mitochondrial extracts from MDA-231 cells treated with or without
cycloheximide and stimulated with OSM or H2O2 were subjected to western blotting and
mitoSTAT3 levels from OSM experiments were quantified in (D) via densitometry analysis.
*p<0.02, Two-way ANOVA, Tukey’s multiple comparisons test; #p=0.005, Two-way ANOVA,
Tukey’s multiple comparisons test. *Courtesy of M. Hyun. (E) STAT3-/- MEFs expressing WT
STAT3 (STAT3a) or the phospho-null mutant (STAT3 S727A) were treated for the indicated
times with OSM and immunoblotted for STAT3 from cytosolic (top panel) or mitochondrial
lysates (bottom panel). Quantification of these results are presented in (F). *p<0.0001, Two-way
ANOVA, Tukey’s multiple comparisons test; #p<0.002, Two-way ANOVA, Tukey’s multiple
comparisons test.
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E. mitoSTAT3 Interacts with Cyclophilin D
Previous reports have linked mitoSTAT3 with regulation of the mitochondrial
permeability transition pore, and in particular, potentially through an interaction with
Cyclophilin D (CypD) (42) . CypD, like other members of the cyclophilin family, is a peptidylprolyl isomerase, that has been broadly implicated as being key for triggering opening of the
permeability transition pore (120) , and is considered an important therapeutic target, particularly
in the context of ischemia-reperfusion injuries. That being said, a major function of prolyl
isomerase proteins is in mediating proper folding of target proteins, which has a significant
impact on protein stability, localization, and activity (81) . While many reports have focused on
protein interactions with CypD in modulating its pore opening function, few have interrogated its
potential role as a chaperone in mediating proper folding of mitochondrial proteins. It is known
though that inhibition of CypD with Cyclosporine A (CsA) drives an unfolded protein response
implicating CypD in protein stability (121) , and that deletion of CypD impairs the status of a
number of mitochondrial proteins (122, 123) .
Interestingly, we noted that STAT3 only becomes competent to bind to CypD after 15’ to
30’ of H2O2 treatment (Figure 16A), which is also likely when STAT3 is being recruited to the
mitochondria following mitoSTAT3 loss (Figure 7). This result was confirmed in purified
mitochondrial extracts incubated with recombinant GST-CypD from cells treated up to 4H with
H2O2 in both WT MEFs (Figure 16B) and 4T1 cells (Figure 16C). In WT MEFs, mitoSTAT3
strongly associates with CypD after 30’ of H2O2 treatment, which is maintained out until 2-4H
after stimulation when mitoSTAT3 levels have returned to baseline (Figure 16B). Notably,
binding of mitoSTAT3 to GST-CypD is maintained out to even 4H in 4T1 mitochondrial lysates,
likely reflecting the longer time it takes for mitoSTAT3 to re-equilibrate following its loss after
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H2O2 treatment in these cells (Figure 16C). Incubation of cyclosporine A (CsA), a known
inhibitor to CypD, during the course of the pulldown blocked the association of mitoSTAT3 with
CypD thereby suggesting against a non-specific interaction (Figures 16B and 16C, lane 6).
This was further confirmed in mitochondria from STAT3+/+ or STAT3-/- MEFs treated with H2O2
(Figure 17A). Bead-bound GST alone did not pulldown any detectable mitoSTAT3 further
supporting the absence of a non-specific interaction (Figure 16D). Immunoprecipitation of
STAT3 from mitochondrial lysates from cells treated for 30’ with H2O2 also show an increased
association between mitoSTAT3 and CypD compared to untreated controls (Figure 16E).
Similar results were seen in human breast cancer cells treated with H2O2 (Figure 17B and C).
Further, proximity ligation assays (PLA) demonstrated an increased association between
mitoSTAT3 and CypD after H2O2 stimulation (Figure 16F). Binding of mitoSTAT3 to CypD
was also observed in MDA-231 cells treated with IL-6, again coincident with the recovery phase
of mitoSTAT3 following stimulation (Figure 16G). These results suggest that upon STAT3’s
re-entry to the mitochondria it binds to CypD, potentially as part of its import and proper folding
mechanism. Similar results were obtained from various cell lines treated with OSM as well
(Figures 17D-F). These results suggest that upon STAT3’s re-entry to the mitochondria it binds
to CypD, potentially as part of its import and proper folding mechanism.
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Figure 16: mitoSTAT3 Interacts with CypD. (A) Lysates from WT MEF whole cell extracts
treated with H2O2 were subjected to pulldown with bead-bound GST-CypD and probed for
STAT3 (Input, lower panels) (B) WT MEFs and (C) 4T1 cells were incubated with H2O2 for
various times prior to isolation of mitochondria. Extracts were incubated with GST-CypD and
STAT3 was assayed by immunoblots (upper panels). Lower panels show the input (10% of that
used for the pull downs). CsA, a CypD inhibitor, incubation during the course of the pulldown
prevents mitoSTAT3 binding (lane 6). (D) 4T1 mitochondria from cells either untreated or
treated with H2O2 were subjected to GST-CypD or GST pull-down. (E) mitoSTAT3 IPs from
MEFs and 4T1 cells treated 30 min with H2O2. Immunoblots were probed for STAT3 (lower
panels) or CypD (upper panels). The fold increase in binding of CypD to mitoSTAT3 was
quantitated and normalized to the untreated sample. The values are shown below the
autoradiographs. (F) Proximity ligation assays in MEFs treated with or without H2O2 for 30
min. PLA complexes were detected by imaging under a Zeiss LSM710 confocal microscope and
quantitated (upper panel as dots/ cell). (G) GST-CypD pulldown of mitoSTAT3 from MDA-231
cells treated with IL-6 and the soluble IL-6Rα with input shown below.
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Figure 17: mitoSTAT3 Inducibly Binds to CypD Following H2O2 or Cytokine Stimulation.
(A) Mitochondrial lysates from STAT3+/+ or STAT3-/- MEFs untreated or treated with H2O2 were
incubated with GST-CypD and probed for STAT3. CsA incubated during the course of the
pulldown shows specificity of the interaction. (B) MDA-231 [ER-/PR-/HER2-] or MDA-435
[ER-/PR-/HER2+] human breast cancer cells were treated for 4H with H2O2 and purified
mitochondria were subjected to GST-CypD pulldown (top panel). Lower panels show the input
(10% of that used for the pull downs). (C) Immunoprecipitation of STAT3 from MDA-231
mitochondria show enhanced association of STAT3 with CypD after H2O2 treatment as
compared to untreated controls. GST-CypD pulldown of STAT3 is induced following OSM
treatment in MDA-231 mitochondria (D), 4T1 mitochondria (E), and in STAT3-/- cells
expressing WT STAT3 (F).
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F. The N-terminus of STAT3 and not S727 is Necessary for Binding CypD
As S727 has been largely implicated as being essential for mitoSTAT3 and a prior report
implicated phospho-S727 in binding to CypD (42) , we evaluated whether or not mutation of
S727 affected STAT3’s interaction with CypD. GST-CypD pulldown of either 293T cells or
STAT3-/- MEFs expressing STAT3 S727A displayed no apparent defects in STAT3-CypD
binding (Figures 18A and C). This was re-affirmed in 4T1 cells expressing STAT3
Y705F/S727A or Y705F/S727D variants, as STAT3 was still capable of interacting with CypD
regardless of S727 status (Figure 18B). It was noted though that mutation of serine 727 to the
phospho-mimetic aspartic acid seemed to increase basal association of STAT3 with CypD,
potentially reflecting that increased S727 phosphorylation of STAT3 may optimize this proteinprotein interaction. However, STAT3β, a C-terminal truncation natural splice variant that lacks
the S727 site, still was competent to bind to CypD following H2O2 treatment (Figure 18D)
suggesting that S727 is dispensable for the binding of STAT3 to CypD.
To further evaluate how STAT3 interacts with CypD we took advantage of an
observation that mitoSTAT1 was unable to bind to CypD (Figure 18E). Using chimeric
STAT3:STAT1 proteins (65, 124) expressed in 293T cells we assessed the region of STAT3
that was necessary for this interaction. Surprisingly, the N-terminus of STAT3 (amino acids 1330 of STAT3) was sufficient to mediate this association as only those constructs containing this
region of STAT3 were induced to bind to CypD following an oxidative insult (Figures 19A and
B). Taking those constructs that contain just the N-terminus of STAT3 (STAT3/1S) versus that
which has the N-terminus of STAT1 and the remaining STAT3 C-terminal portion (STAT1/3S)
produced similar results (Figure 19C). Interestingly, binding of STAT3 to CypD can be recapitulated in a cell free system using cell extracts that are warmed to 30oC. This was observed
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both from 293T cells over-expressing STAT3 and even with endogenous protein from purified
mitochondria from MDA-231 cells (Figures 19D and E). In both cases, binding of STAT3 to
CypD is inhibited in the presence of CsA, and STAT3 is not detectable in lysates incubated with
GST alone (Figures 19D and E). Further, MDA-231 mitochondrial lysates warmed to 30
degrees showed selective increases in mitoSTAT3 binding to CypD with no effect on another
known binding partner of CypD (ATP5O, Figure 19E). To our knowledge this is the first
instance of a cell free system being utilized to study a mitochondrial signaling cascade, and
provides a useful tool for interrogating how the interaction of mitoSTAT3 and CypD is
regulated.
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Figure 18: S727 is Dispensable for the mitoSTAT3-CypD Interaction. (A) Expression of
Flag-STAT3 WT or -S727A STAT3 in 293T cells was followed by H2O2 treatment and resulting
whole cell extracts were incubated with GST-CypD and probed for Flag. (B) 4T1 cells
expressing the mutant STAT3 isoforms Y705F/S727A or Y705F/S727D were treated with H2O2
and STAT3 was immunoprecipitated from mitochondrial extracts and probed for CypD. (C)
STAT3-/- MEFs were transduced with retroviral constructs to drive expression of WT STAT3
(STAT3α) or the phosphorylation defective mutants (S727A, Y705F). GST CypD Pulldown
was performed on these cells after H2O2 treatment, which showed no obvious defect in
mitoSTAT3 binding when S727 is manipulated. (D) STAT3 null cells expressing STAT3β, a Cterminal truncation mutant that lacks the S727 site, also inducibly binds to CypD. (E) GSTCypD pulldown of mitochondrial STAT1 after H2O2 treatment.
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Figure 19: Binding of mitoSTAT3 to CypD is Mediated through STAT3’s N-terminus and
can be re-capitulated in a cell free system.
(A) 293T cells expressing various chimeric versions of STAT3/STAT1 were treated with H2O2
and whole cell extracts were incubated with GST-CypD and probed for Flag (upper panel).
Lower panels show the input (10% of that used for the pull downs). (B) Diagram of the chimeric
constructs used in (A) indicating the critical region in STAT3 that mediates its binding to CypD
(65) . (C) 293T cells expressing STAT3/1S or STAT1/3S were treated for 30’ or 1H with H2O2,
subjected to GST-CypD pulldown and probed for Flag (pulldown: top panel, input: bottom
panel). (D) 293T cell lysates expressing STAT3/1H were warmed to 30 degrees and incubated
with either GST-CypD or GST alone and immunoblotted for Flag. CsA was incubated with
warmed lysates to also show specificity of the interaction (lane 5). Bottom panel depicts
Coomassie stain for GST-CypD and GST. (E) Mitochondrial lysates from MDA-231 cells tested
in the cell free system were incubated at 30 degrees and a GST-CypD pulldown was performed
in the presence or absence of CsA with immunoblotting for STAT3 and ATP5O (OSCP subunit
of Complex V that CypD is known associates with).
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G. Mechanistic Insights into the STAT3-CypD Interaction
In order to explore the functional impact of mitoSTAT3 binding to CypD we attempted to
better characterize the domain and/or post-translational modification (s) in STAT3 that was
required for this association. Various N-terminal deletion constructs of STAT3 were expressed
in 293T cells and treated with H2O2 to drive binding to CypD. Cells where the entire N-terminal
domain (amino acids 1-138, Δ138) was deleted were no longer competent to associate with
CypD (Figure 20A). To further investigate whether the N-terminal domain (NTD) of STAT3
was sufficient for its interaction with CypD we generated constructs of STAT3 that encoded the
first 138, 150, or 200 amino acids of STAT3 and expressed them in STAT3-/- MEFs. The NTD
fragment alone of STAT3 was able to effectively bind to CypD following treatment with H2O2
(Figure 20B). These results suggest that the NTD of STAT3 may be both necessary and
sufficient to drive the mitoSTAT3-CypD association. However, expression of those same
STAT3 constructs in 293T cells seemed to implicate that a portion of the coiled-coil domain of
STAT3 might also be required for CypD binding (Figure 20C). And at times Δ138 STAT3 is
able to bind to CypD, but the interaction is not inducible (data not shown). These
discrepancies may be a reflection of effects of endogenous STAT3 protein in 293T cells in
competing with the expressed STAT3 constructs or alternatively, may suggest a more complex
regulation of the association than currently appreciated.
Attempts to pinpoint a post-translational modification of STAT3 as being key for
facilitating its binding to CypD have been largely unsuccessful. Mutation of 13 known and
potential phosphorylation sites at the C-terminus of STAT3 had no impact on the observed
interaction (data not shown). Peptidyl-prolyl isomerases tend to target proline residues
immediately downstream of phospho-S/T residues, though the exact recognition motif for the
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cyclophilin family of prolyl isomerases is unclear (81) . STAT3 has three such target sites, two
of which are viable candidates (T714, S727) and both of which have been shown to be
phosphorylated (125) . To exclude this possibility, such proline residues in STAT3 were
mutated to alanine, but neither alone or in combination were these sites able to attenuate
mitoSTAT3’s binding to CypD (data not shown). This is not surprising, as we now know that
the N-terminus of STAT3 is critical for this association. However, this does not exclude the
possibility that CypD’s isomerase activity is targeted against one of these proline residues, which
may be critical for not only mediating proper folding of mitoSTAT3 but also potentially
regulating its function. Future studies will more closely interrogate this possibility.
There are a number of reported post-translational modifications that have been reported at
the N-terminus of STAT3. We investigated a number of them including K49, which has been
shown to be acetylated and methylated (126, 127) , K87, a known acetylation site (128) , Y45,
which has been reported to be phosphorylated following IL-6 stimulation (129) , C108, a key
oxidation site in STAT3 (64, 105) , and K140, also shown to be methylated (130) . Mutation of
these sites did not abrogate STAT3’s ability to bind to CypD (Figure 20D and E, data not
shown). We noticed, however, that conversion of STAT3 Y45 to phenylalanine facilitated an
increased basal association of STAT3 with CypD and also potentiated the H2O2 inducible
binding (Figure 20E). As mutation of Y45 to phenylalanine increased STAT3-CypD binding
we postulated that dephosphorylation of STAT3 might be involved in this process.
Indeed, incubation of lysates with λ phosphatase enhanced the interaction of STAT3 with
CypD (Figure 21A). Moreover, pre-treatment of cells with the tyrosine phosphatase inhibitor
vanadate (sodium orthovanadate, Na3VO4) blocked H2O2 driven STAT3-CypD interactions
(Figure 21B). Inhibition of tyrosine phosphatases similarly reduced binding of STAT3 to CypD
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in the cell free system model (Figure 21E). Vanadate pre-treatment also suppressed STAT3
Y45F mutant constructs binding to CypD, likely ruling out this site as the phosphatase target site
(Figure 21C). Phosphatase mediated activity is ATP independent so to confirm that a
phosphatase was involved in this pathway, cell lysates were dialyzed to remove ATP. Taking
advantage of the cell free system established above for analyzing this interaction, we noted that
dialyzed lysates still inducibly bound to CypD, as did those incubated with the broad-spectrum
kinase inhibitor staurosporine (Figure 21D). All of these results supported the idea of a
phosphatase-mediated pathway culminating in STAT3-CypD complex formation. This is
particularly interesting as most phosphatases are inhibited in the presence of H2O2, which
strongly induces binding of STAT3 to CypD, because of oxidation of key cysteines in their
catalytic pocket (131) . One of the major regulators of STAT3 signaling is the Src homology-2
domain containing protein tyrosine phosphatase-2 (SHP2) (132) . Coincidentally, SHP2 is also
paradoxically activated by oxidative stress (133) , and it can localize to the mitochondria where
it is known to regulate mitoSTAT3 (134) . However, knockdown of SHP2 in MDA-231 cells
did not block STAT3-CypD interactions (Figure 21E), and as such, the identity of this
phosphatase will be the subject of future work.
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Figure 20: The NTD of mitoSTAT3 May Be Sufficient for Interactions with CypD.
(A) 293T cells expressing STAT3 constructs with the indicated amino acid deletions from the Nterminus were treated with H2O2 for 1H and subjected to GST-CypD pulldown. (B) STAT3 Flag
tagged N-terminal fragments (1-138, 1-150, or 1-200) were transfected into STAT3-/- MEFs and
treated with H2O2. GST-CypD pulldown (left panel) or corresponding input (right panel) was
immunoblotted for Flag (STAT3). (C) Experiment from (B) was repeated in 293T cells. The
corresponding input (left panel) and GST-CypD pulldown samples (right panel) were probed for
Flag (STAT3). (D) Analysis of key lysine mutants of STAT3 expressed in 293T cells show no
defect in H2O2 induced CypD binding. 4KR: K679R, K685R, K707R, and K709R; 6KR: 4KR +
K49R and K87R. (E) Mutation of Y45 in STAT3 increases H2O2 the inducible STAT3-CypD
binding, whereas mutation of a nearby residue (S40) has no effect. STAT3 mutants were
expressed in 293T cells and Input (top panel) and GST-CypD pulldown extracts (bottom panel)
were probed for Flag (STAT3).
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Figure 21: A Phosphatase Mediated Event Drives mitoSTAT3-CypD Interactions.
(A) Extracts from 293T cells expressing the chimeric construct STAT3/1S were subjected to λ
phosphatase treatment and GST-CypD pulldowns were performed. Levels of pERK1/2 are
shown to confirm λ phosphatase activity. (B) 293T cells expressing STAT3/1S were pre-treated
with either Vanadate (Na3VO4) or Staurosporine followed by treatment with H2O2 for 1H.
Untreated lysates were also subjected to λ phosphatase treatment or mock treatment (same
conditions as λ phosphatase assay without enzyme). GST-CypD pulldown was performed
showing lack of binding of STAT3 in the presence of Vanadate (lanes 3 and 4). Mock treatment
of samples alone once again was sufficient to induce the interaction of STAT3 with CypD (lanes
7 and 8). (C) Vanadate pre-treatment also blocks the inducible binding of the Y45F STAT3
mutant. Flag-tagged STAT3 WT or Y45F mutants expressed in 293T cells were pre-treated for
30min. with Vanadate (Na3VO4) followed by 1H H2O2 treatment. GST-CypD pulldown and
Input probed for Flag (STAT3) are shown. (D) Extracts from 293T cells expressing STAT3/1H
were dialyzed for 3H (10,000MWCO dialysis tubing) prior to mock treatment (30o) with or
without the addition of ATP (20mM). Staurosporine was included during the mock treatment
period for lysates in lanes 4 and 5, which also showed no effect on the binding of STAT3 and
CypD as assessed by GST-CypD pulldown. (E) Vanadate (Na3VO4) also reduces the interaction
of STAT3 and CypD in the cell free system model with 30o treatment for 30’ in cell lysates
containing STAT3/1S subjected to GST-CypD pulldown. (F) Knockdown of the tyrosine
phosphatase SHP2 in MDA-231 mitochondrial extracts or whole cell lystates (WCE) does not
inhibit binding of STAT3 to CypD in the cell free system model. Extracts were immunoblotted
for STAT3 or SHP2. Scr (non-targeting shRNA control), Sh (shRNA against SHP2).
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H. CypD May Be Required for the Stability of mitoSTAT3 Following Stimulation
As STAT3 associates with CypD upon its return to the mitochondria and considering
CypD’s role as a chaperone protein, we hypothesized that CypD might be important for the
stability of mitoSTAT3 after a stimulus. However, mitoSTAT3 levels were similarly affected in
both CypD+/+ and CypD-/- MEFs (Figure 22A) with the latter only showing a slight defect. Pretreatment with CsA also did not affect mitoSTAT3 levels, suggesting that CypD may not be
necessary for the full recovery of mitoSTAT3 after H2O2 or cytokine treatment (Figures 22B
and C). The results with CsA also point to a MPTP independent role in the regulation of
mitoSTAT3 levels as CsA is known to prevent permeability transition. We had previously
observed that there were cleavage fragments of mitoSTAT3 that were not detectable in cytosolic
extracts probed for STAT3 (data not shown). Though we had not seen gross differences in fulllength mitoSTAT3, preliminary data showed that CypD-/- cells had a greater portion of ‘cleaved’
mitoSTAT3 after treatment as compared to their WT counterparts (Figure 22D). More work is
needed to clarify this possibility. This may implicate CypD as being necessary for protecting
mitoSTAT3 from proteolytic cleavage, and stabilizing it after a stimulus. This is consistent with
our observation that mitoSTAT3 seems to bind to CypD upon its re-accumulation in the
mitochondria, rather than upon the initial stress. Based on our knowledge that the full recovery
of mitoSTAT3 is cycloheximide sensitive (Figure 15C) we examined whether or not cells
lacking CypD were more heavily reliant on protein synthesis to maintain mitoSTAT3 levels.
Preliminary data suggests this to be the case as mitoSTAT3 levels decreased in CypD-/- MEFs
treated with cycloheximide more readily than CypD+/+ MEFs (Figure 22E). All together, CypD
appears to be an important binding partner and regulator of mitoSTAT3.
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Figure 22: CypD May Be Important in the Stability of mitoSTAT3 After Stimulation.
(A) CypD+/+ MEFs and CypD-/- MEFs were treated for the indicated times with OSM and
isolated mitochondrial lysates were resolved via SDS-PAGE and immunoblotted for STAT3,
pERK1/2, NDUFA9 (loading control) and CypD. WT MEFs (B) or MDA-231 human cancer
cells (C) were pre-treated with CsA (1H in MEFs; 4H, 10µg/mL in MDA-231 cells) and either
treated with H2O2 or OSM and mitochondrial lysates were probed for mitoSTAT3. (D) CypD+/+
MEFs and CypD-/- MEFs were treated for the indicated times with OSM and isolated
mitochondrial lysates were immunoblotted for STAT3 (N-terminal STAT3 antibody). Cleavage
products were detected as indicated. (E) CypD+/+ MEFs and CypD-/- MEFs were incubated with
cycloheximide for 2 or 4H and mitoSTAT3 levels were assessed from purified mitochondrial
extracts.
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I. mitoSTAT3 Interacts with Other Chaperone Proteins and Components of the MPTP
It is currently unclear as to whether or not mitoSTAT3 binds directly to CypD, or as part
of a shared complex. Though commonly presented in a linear fashion, it is likely that most
mitochondrial processes are mediated through large multi-meric complexes (135) . In concert
with this idea, expression of STAT3 in an in vitro reticulocyte system was not competent to bind
to recombinant GST-CypD, either basally or after stimulation (Figure 23A). We therefore
hypothesized that other proteins may be required for this interaction, potentially as part of a
shared complex, that were missing from this cell free system. To evaluate this we utilized
transgenic mice expressing a transcriptionally inactive and mitochondrial targeted form of
STAT3 (MLS-STAT3E) (11) . We were able to induce binding of mitoSTAT3 to CypD in
mitochondria isolated from hearts utilizing to an ex vivo ischemia model (11) (Figures 23B and
C). Moreover, the association of mitoSTAT3 to CypD could be re-capitulated in the cell free
system by warming mitochondrial lysates, reflecting that what is observed in cell culture models
is conserved in a relevant in vivo heart model. Using this information, we performed mass
spectrometry analysis from heart mitochondrial lysates that had been subjected to either a GSTCypD pulldown or STAT3 immunoprecipitation looking for shared components. Interestingly,
some of the largest hits we obtained for both experimental conditions were for other reported
members of the permeability transition pore complex including ADP/ATP Translocase,
phosphate carrier, and components of Complex V of the electron transport chain, the latter which
is now thought to form the core of the pore (45, 136) (Table 4). They also interestingly seemed
to increase in abundance under the ischemic conditions suggesting regulation of this
mitochondrial complex.
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An additional mass spec analysis was performed in order to identify post-translational
modifications of mitoSTAT3 after ischemia that might facilitate its association with CypD.
There were no differences in the observed modifications of mitoSTAT3 (O-methylation of
residues D261, D369, and D723 with oxidation of M726) between baseline and ischemic
conditions (data not shown). It is currently unclear whether any of these modifications impact
mitoSTAT3 or its regulation. Further information gleaned from these studies demonstrated that
mitoSTAT3 also interacted with other mitochondrial molecular chaperones. This included
Tumor Necrosis Associated Factor-1 (TRAP1), which is a mitochondrial member of the Hsp90
family, 60kDa heat shock protein (Hsp60), and stress-70 protein (Hspa9) (data not shown). Not
only are these proteins important for proper folding of newly imported mitochondrial proteins,
but they also are involved in MPTP regulation (137, 138) . Future work will address the role of
these proteins in regulating mitoSTAT3 and its downstream mitochondrial targets.
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Figure 23: Use of an In Vivo Heart Model to Study mitoSTAT3 Binding Partners.
(A) Reticulocyte In-vitro translated STAT3 was either treated or untreated with H2O2 and
incubated with GST-CypD showing no detectable interaction between purified STAT3 and
recombinant CypD. (B) Transgenic mice expressing MLS-STAT3Eo were subjected to ex vivo
stop flow ischemia and mitochondrial lysates were incubated with GST-CypD. Pulldowns (top
panel) and input (bottom panel) were probed for STAT3. (C) STAT3 immunoprecipitation from
mitochondrial lysates from transgenic MLS-STAT3Eo animals also demonstrate an increased
interaction between mitoSTAT3 and CypD after ischemia. (D) Heart mitochondrial extracts
from MLS-STAT3Eo mice also become competent to bind to CypD after mock (30 degrees)
treatment, to the same extent as ischemia conditions alone (lane 3 versus lanes 2 and 4).
*Ischemic hearts kindly provided by Dr. Karol Szczepanek, Ph.D.
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Table 4: Interacting Partners of CypD and mitoSTAT3. Mitochondrial extracts from control
transgenic hearts expressing MLS-STAT3Eo or those subjected to ex vivo stop flow ischemia
were subjected to either a GST-CypD pulldown or STAT3 Immunoprecipitation and bound
proteins were analyzed via mass spectrometry. Those highlighted in yellow reflect known
components of the MPTP. Delta=Ischemia-Control spectra counts
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II. mitoSTAT3 Regulation and CypD Association in Controlling Mitochondrial Function
A. Regulation of MPTP by mitoSTAT3
Previous reports have implicated that mitochondrial STAT3 is linked to control of the
mitochondrial permeability transition pore (MPTP). While under non-stressed conditions the
pore transiently opens and closes to maintain calcium concentration gradients and mitochondrial
membrane potential, sustained opening of the pore leads to mitochondrial swelling, dysfunction,
and rupture of the outer mitochondrial membrane resulting in cell death (47) . The latter can
occur in response to excess mitochondrial ROS, elevated Ca2+ content, or the accumulation of
misfolded mitochondrial proteins. MitoSTAT3 has been shown to inhibit pore opening (42) ,
and therefore, is considered protective against MPTP mediated cellular damage, particularly in
ischemia-reperfusion injuries (17, 139) . To date, no reports have evaluated the role of STAT3
in MPTP regulation in cell culture models. Considering the loss and recovery of mitoSTAT3
that we observed with a number of stimuli and its subsequent association with CypD, we
evaluated whether or not changes in MPTP opening coincided with these signaling events.
Using the established Calcein/CoCl2 method for measuring pore opening, we noted that
no changes in dye were observed following OSM stimulation over a period where mitoSTAT3
levels are dynamically regulated (Figure 24A). This was in contrast to H2O2 treatment of cells,
which showed the anticipated decrease in calcein dye retained indicative of MPTP opening
(Figure 24A). The difference observed between OSM and H2O2 treatment in terms of MPTP
opening likely points to the idea that changes in mitoSTAT3 levels and binding to CypD may not
be related to permeability transition. Moreover, though initial experiments suggested that cells
lacking STAT3 were more susceptible to pore opening following an oxidative insult (Figure
24B) further experiments showed the defect, if any, to be more subtle (Figure 24C). Calcium
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retention capacity assays from digitonin permeabilized cells also showed marginal effects on
MPTP sensitivity in the absence of STAT3, with a trend towards less calcium being retained in
STAT3 null cells (Figure 25A). Oddly, expression of STAT3 in a STAT3 null background in
both MEFs and hepatocytes increased the sensitivity of the MPTP (Figures 25B and C, green
traces) with less calcium being required to trigger opening (increased calcium green 5N
fluorescence). One consequence of MPTP regulation is effects on intra-mitochondrial calcium
content, though no differences were observed in rhodamine-2 staining (Rhod-2, intramitochondrial calcium sensor) after OSM treatment in the early setting where loss of
mitoSTAT3 is observed (Figure 25D). Coupled together, loss of mitoSTAT3 and its interactions
with CypD may work upstream of the MPTP with functional changes only being observed under
ideal conditions. This is in concert with a prior report that demonstrated STAT3’s effects on the
pore were only manifested in the presence of ADP and MgCl2, which stimulate respiration and
greatly increase the threshold for MPTP opening (42) . Proper fine-tuning of the ETC by
mitoSTAT3, particularly under conditions of stress then, may equate to downstream changes in
permeability transition independent of its association with CypD.
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Figure 24: Unclear Effects on MPTP Regulation by mitoSTAT3.	
  
(A) Cells loaded with Calcein-AM/CoCl2 were assayed for MPTP opening following treatment
with either OSM or H2O2. Live cell imaging performed using a Zeiss Cell Observer Spinning
Disc confocal microscope (63X objective) demonstrated that over 15’ of OSM treatment (top
panels; the time period that encompasses mitoSTAT3 loss and recovery) no changes were
observed in total dye retained indicating a lack of MPTP opening. This is in contrast to H2O2
treatment of cells where there is less dye retained after stimulation. *Images taken with the
assistance of Dr. Scott Henderson. (B) Initial experiments using Calcien/CoCl2 assays
implicated STAT3 as being important in regulating MPTP opening following H2O2 treatment.
WT MEFs, STAT3-/- MEFs, and CypD-/- MEFs (as a control) were treated for 2H with H2O2 and
the amount of Calcein dye retained was measured via flow cytometry. (C) When repeated and
normalized to their untreated control, STAT3-/- MEFs showed only a mildly increased
susceptibility to MPTP opening that was not significantly different from STAT3+/+ MEFs after
2H H2O2 treatment.
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Figure 25: Calcium Retention Capacity Assays show No Defect in MPTP Regulation in the
Absence of STAT3.
Calcium retention capacity assays (CRC) in WT MEFs .(A and B) or Hepatocytes (C) show no
statistically significant differences in MPTP susceptibility in the presence or absence of STAT3.
(A) Quantification of the average number of 10µM Ca2+ pulses required to trigger MPTP
opening. (B) Representative traces of STAT3+/+ MEFs, STAT3-/- MEFs, or STAT3-/- MEFs reconstituted with WT STAT3 from CRC assays. Each spike in Calcium Green 5N fluorescence
indicates a single 10µM Ca2+ pulse. Note that STAT3-/- cells expressing WT STAT3 (green
tracing) show enhanced susceptibility to MPTP regulation as denoted by the increased rate to an
unopposed increase in Calcium Green 5N fluorescence. (C) Similar results as in (B) were
obtained from STAT3+/+ hepatocytes, STAT3-/- hepatocytes, or STAT3-/- hepatocytes expressing
WT STAT3 subjected to CRC assays. (D) Flow cytometric analysis of Rhodamine-2 (Rhod-2,
intra-mitochondrial calcium content) staining in STAT3+/+ or STAT3-/- MEFs treated with OSM
or H2O2 for the indicated times.
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B. Cytokines Do Not Drive Acute Changes in Oxygen Consumption
Though we did not observe changes in MPTP with OSM treatment, we postulated that
cytokine treatment might modulate respiratory rates through dynamic changes in mitoSTAT3,
which is important in optimizing the ETC (1) . Cytokines have been shown to regulate
mitochondrial oxygen consumption (140) , and IL-6, in particular, mediates supercomplex
assembly that is dependent on STAT3 (15) . The formation of supercomplex respirasomes (14)
is essential for efficient functioning of the ETC and optimal respiratory capacity. However,
OSM treatment similarly promotes supercomplex assembly in the presence or absence of
STAT3, with no apparent defect in STAT3 null cells under basal conditions (collaboration with
Dr. Jared Rutter’s lab, University of Utah, personal communication, data not shown). Further,
we observed no significant changes in oxygen consumption in WT MEFs or MDA-231 cells
treated with OSM (Figures 26A and B) consistent with a prior report (15) . Therefore, the loss
and recovery of mitoSTAT3 and binding to CypD does not acutely regulate respiratory capacity.
At this time, however, we can’t rule out that the acute changes in mitoSTAT3 and its interacting
partners don’t drive downstream events that culminate in later altered mitochondrial function.
C. STAT3 Effects on Mitochondrial Membrane Potential are Cell Dependent
Numerous reports have implicated STAT3 as being important in the regulation of the
mitochondrial membrane potential (2, 15, 16) with STAT3’s mitochondrial localization being
membrane potential dependent (6) . Electron micrograph images of mitochondria from STAT3/-

cells show swollen mitochondria with disrupted cristae likely reflecting more damaged

mitochondria in the absence of STAT3 (141) . Consistent with this we also observed a sharp
decrease in the resting mitochondrial membrane potential using the cationic dye tetramethyl
rhodamine ethyl ester (TMRE) in the absence of STAT3 (Figure 26C) that was partially
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normalized via treatment with CsA. This suggests the defect in mitochondrial potential in
STAT3-/- cells partly depends on CypD mediated MPTP opening, though increased MPTP
opening under these conditions may be downstream of larger mitochondrial dysfunction. Using
the ratiometric dye JC-1, which aggregates in mitochondria with increasing membrane potential,
we noted a similar defect in STAT3-/- MEFs (Figure 26D, upper panel). However, other cell
lines lacking STAT3 did not recapitulate this phenotype including STAT3 KO hepatocytes
(Figure 26D, bottom panel) and human cancer cell lines where STAT3 had been depleted via
shRNA (data not shown). Once again this points to cell type and context dependent functions
of mitoSTAT3 making larger scale conclusions about its overall function challenging.
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Figure 26: mitoSTAT3’s effects on Oxygen Consumption are Independent of its Regulation
by Cytokines and STAT3 Exhibits Cell-Type Specific Effects on Membrane Potential.
WT MEFs (A) or MDA-231 cells (B) were treated with OSM or IFNγ (which does not drive loss
of mitoSTAT3) in the presence or absence of the Jak inhibitor Ruxolitinib and oxygen
consumption was monitored using a XF24 Extracellular Flux Analyzer (Seahorse Bioscience).
Oxygen consumption rates are plotted as % of 0 minutes for each treatment condition. (C)
Mitochondrial membrane potential as assessed by TMRE loading and flow cytometry analysis in
STAT3+/+ or STAT3-/- MEFs either in the presence or absence of CsA (6H pre-treatment prior to
membrane potential determination). (D) STAT3+/+ and STAT3-/- MEFs or hepatocytes were
loaded with the ratiometric dye JC-1 and imaged with a Zeiss 710 inverted confocal microscope
(20X objective) using 488 (monomer) and 585 (aggregate) laser excitation. Increasing JC-1
aggregates is indicative of increased mitochondrial membrane potential and demonstrates celltype specificity in control of membrane potential.
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D. H2O2, but not OSM, Alters Membrane Potential and Mitochondrial ROS Production
In further trying to characterize the functional significance of the loss and recovery of
mitoSTAT3, we examined the mitochondrial membrane potential and mitochondrial ROS
production after stimulation. MitoSTAT3 has been shown to be an important player in
regulation of mitochondrial ROS levels (11, 104) , and consistent with these reports we see a
more steady increase in mitochondrial superoxide production following H2O2 treatment (Figure
27A). Moreover, knockdown of STAT3 in MDA-231 human breast cancer cells led to a strong
basal increase in mitochondrial ROS levels (Figure 27B). Considering this data and published
literature, we hypothesized that the initial loss (or even the recovery phase where we see binding
to CypD) of mitoSTAT3 might lead to changes in ROS levels. Treatment with OSM had no
impact on mitochondrial ROS production or in affecting mitochondrial membrane potential
(Figure 27C). This was in stark contrast to H2O2 treatment of WT MEFs where following an
initial hyperpolarization, mitochondria rapidly depolarized, which was associated with
significant increases in ROS levels (Figure 27C). Similar results were obtained in MDA-231
cells, where OSM treatment also had little effect on these mitochondrial functional parameters
(Figure 27D). The dichotomy we observe in responses between these stimuli, despite their
similar regulation of mitoSTAT3, may suggest that an alternative approach to uncovering the
biological relevance of mitoSTAT3 signaling is necessary going forward.
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Figure 27: H2O2, but not OSM, Alters Membrane Potential and Mitochondrial ROS
Production.
(A) STAT3+/+ or STAT3-/- MEFs treated for the indicated times with H2O2 were loaded with
mitoSOX (detects mitochondrial superoxide production) and analyzed via flow cytometry.
p<0.05, Student’s T-test. (B) MDA-231 cells expressing either a non-targeting shRNA (shScr)
or a shRNA against STAT3 (shSTAT3) were loaded with mitoSOX and visualized via confocal
imaging (Zeiss 710, 20X). (C) WT MEFs treated with either OSM or H2O2 were analyzed for
changes in either mitochondrial membrane potential (TMRE) or mitochondrial ROS production
(MitoSOX) via flow cytometry. Only significant changes were noted in H2O2 cells. *p<0.01,
Student’s T-test as compared to control. (D) MDA-231 cells were treated and analyzed as in (C)
and confirmed the selective effects of H2O2 on mitochondrial functional parameters.
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E. Mitochondrial and Nuclear-encoded Transcript Regulation by MitoSTAT3
As STAT3’s canonical role is as a transcription factor we tested whether or not changes
in mitoSTAT3 levels were correlated with alterations in mitochondrial-encoded genes.
MitoSTAT3 has been shown to repress mitochondrial transcription in keratinocytes (107) ,
whereas it supports increased mitochondrial transcription in embryonic stem cells, which is a key
determining factor in the maintenance of ‘stemness’ (142) . In order to examine this, we treated
MEFs with OSM in the presence or absence of the Jak inhibitor Ruxolitinib, which we have
previously shown blocks the loss of mitoSTAT3 under these conditions (Figure 11A).
However, OSM had little effect on mitochondrial encoded RNA’s, and there was no difference
detected in mitochondrial transcript levels in those cells that had been pre-treated with
Ruxolitinib (Figure 28A).
Though the export of mitochondrial proteins has not been well studied, there is precedent
for resident mitochondrial proteins translocating to the nucleus under conditions of stress to drive
a mitochondrial-skewed nuclear program (143, 144) . The best evidence for this occurring is
with single stranded DNA binding protein 1 (SSBP1), which normally binds mitochondrial
DNA, but under stress, traffics to the nucleus to increase the gene expression of mitochondrial
chaperones as an adaptive response (143) . Considering STAT3’s role as a nuclear transcription
factor, and its initial loss from the mitochondria following stress and subsequent nuclear
increase, we hypothesized that STAT3 might be assuming a similar role in connecting the
mitochondrial and nuclear programs. To investigate this possibility we performed a microarray
comparing WT MEFs and STAT3-/- MEFs both under basal conditions and after OSM
stimulation. Results from these arrays implicated genes potentially in the mitochondrial
unfolded protein response and mitonuclear communication pathway (145) as being relevant
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STAT3 targets, which included Heme Oxygenase 1 (HMOX1), Activating Transcription Factor
3 (ATF3), and Nuclear Transcription Factor Y subunit beta (Nfyb), amongst others (Table 5).
These results were confirmed via qPCR and demonstrated a defect basally in STAT3-/- MEFs in
genes important for this stress response pathway (Figure 28B) with some dependency on
mitoSTAT3 [MLS-STAT3] (ATF3 and HMOX1).
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Figure 28: Impact of mitoSTAT3 on Mitochondrial and Nuclear Encoded Transcripts.
(A) RNA was isolated from WT MEFs treated for the indicated times with OSM in the presence
or absence of Ruxolitinib, and after cDNA generation, qPCR analysis was performed on the
following subset of mitochondrial encoded transcripts: ND6 (Complex I of the ETC, light strand
of mtDNA), Cytb (Complex III of the ETC, heavy strand of mtDNA), COXII (Complex IV of
the ETC, heavy strand of mtDNA), ATPase6 (Complex V of the ETC, heavy strand of mtDNA);
N=4. (B) Genes implicated in extra-mitochondrial signaling as identified from the microarray
analysis were validated via qPCR in STAT3+/+ and STAT3-/- MEFs, and STAT3-/- cells
expressing MLS STAT3. N=4, no statistically significant changes.
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Table 5: Microarray Data. Genes shown below (top 150 hits) are those that were uniquely upregulated in STAT3+/+ MEFs, as compared to their STAT3-/- counterparts, following OSM
stimulation with their respective fold change. Those highlighted in yellow have been shown to
play a role in mitochondrial retrograde signaling to the nucleus. Microarray analysis was
performed by Dr. Catherine Dumur.
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F	
  . STAT3 in Mitochondrial Quality Control
Because of the defect we observed in gene expression under basal and stimulated
conditions in the STAT3-/- MEFs, particularly in genes involved in the mitochondrial unfolded
protein response, we hypothesized that STAT3 might be involved in mitochondrial quality
control. STAT3 is known to suppress autophagy (146) , and the connections between autophagy
and mitophagy are well established (147) . Proper identification and clearance of mitochondria
through the mitophagy pathway, which uses the same machinery as the classical autophagic
cascade, is now recognized as an important player in a number of pathological states (148) .
Using the mitochondrial ETC inhibitors oligomycin (Complex V inhibitor) and antimycin a
(Complex III inhibitor) to drive mitophagy (149) , we observed a more potent effect in STAT3-/cells (Figure 29A) with the mitochondrial pool assuming a punctated morphology indicative of
lysosomal trafficking. This differed from STAT3+/+ MEFs, which retained a more normal
mitochondrial morphology after treatment, and as such had a greater mitochondrial area and
length than their STAT3 null counterpart (Figure 29B). Similarly, more mitochondria from
STAT3-/- MEFs co-localized with the lysosomal dye Lysotracker Red after mitophagy induction
suggesting that in the absence of STAT3 mitochondria may be more readily cleared after stress
(Figure 29C). Interestingly, both STAT3 and CypD have been implicated in mitochondrial
homeostasis as in their absence, mitochondria are more likely to be found enclosed in double
membrane intracellular structures, likely as part of their clearance through the lysosomal
degradation pathway (10, 150) . Work is ongoing to clarify the role of changes in mitoSTAT3
levels and its binding to CypD in mitochondrial quality control.
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Figure 29: STAT3’s Role in Mitochondrial Quality Control.
(A) The mitochondrial morphology of STAT3+/+ or STAT3-/- MEFs stably expressing mito-YFP
under control conditions or after 24H of OA (10µM Oligomycin, Complex V inhibitor; 4µM
Antimycin A, Complex III inhibitor) to induce the mitochondrial unfolded protein response. (B)
Quantification of mitochondrial area and length under these conditions as determined by ImageJ
quantification as previously described (151) ; p<0.01, Student’s T-test. (C) STAT3+/+ or
STAT3-/- MEFs stably expressing mito-YFP under control conditions or after 24H of OA as in
(A) were co-stained with Lysotracker Red (50nM, 30’ pre-treatment and left in during imaging
to avoid blebbing) to stain lysosomes. Arrows indicate co-localization. All images were taken
via live cell imaging with a Zeiss 710 inverted confocal microscope (63X objective). Inset
shows magnified region as outlined in original image.
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G. Role of the mitoSTAT3-CypD Axis in Chemotherapeutic Resistance
It is well known that STAT3 is a key driver of a number of cancers, and that blockade of
its nuclear transcriptional program has shown promise in pre-clinical cancer therapeutic trials
(37) . Additionally, STAT3 inhibition in the context of chemotherapeutic or radiation resistance
has shown some efficacy in restoring sensitivity and promoting cancer cell killing (152-156) .
Although a number of STAT3 inhibitors have been developed to limit this nuclear function
(103) , they have had little value clinically, which may be due to their ineffectiveness in limiting
the mitochondrial actions of STAT3. Indeed, mitoSTAT3 has been shown to be important not
only for Ras transformation (2) , but also for the continued growth of already transformed cells.
This includes but is not limited to breast cancer cells (33) , myeloproliferative disorders (157,
158) , and pancreatic cancer neoplasms (38, 39) . Coupled with the knowledge that STAT3 is
relevant in autophagy, and potentially mitophagy, and the role these two processes play in cancer
progression and therapeutic resistance (159-161) we explored how chemotherapeutic treatment
affected mitoSTAT3 levels.
To address the potential role of mitoSTAT3 in drug resistance, we incubated 4T1 cells
with doxorubicin for 24, 48 or 72hr and analyzed STAT3 levels from mitochondrial and
cytosolic fractions. Although there was a time-dependent increase in mitoSTAT3 (Figure 30A),
levels of STAT3 in the cytosol were unchanged (Figure 30B, quantification Figure 30C).
Interestingly, the binding of mitoSTAT3 with CypD increased after doxorubicin treatment
(Figure 30D). We also prepared mitochondria and cytosol from 4T1 cell-derived tumors grown
in mice (Figure 30 E, F, and G). Mice were treated with or without doxorubicin 7 days after
inoculation with 4T1 cells either every 3 days (5 injections) or every 7 days (3 injections). No
changes were observed in cytosolic or nuclear (data not shown) STAT3 from tumors of mice
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treated with or without doxorubicin. However, levels of mitoSTAT3 were elevated in mice
injected with doxorubicin (Figure 30E), and levels were higher in animals given doxorubicin
every 3 days than every 7 days (~ 5 vs. 2,5 fold; Figure 30 F and G). In fact the increase in
frequency of drug administration tightly correlated with the increase in mitoSTAT3 levels
(Figure 30H). As 4T1 cells are resistant to 6-thioguanine, metastatic lesions can be readily
isolated from digested tissue and grown in culture. Metastatic cells isolated from the liver of
doxorubicin treated animals maintained the difference in mitoSTAT3 levels seen from the
primary tumor indicative that this change is likely persistent (Figure 30I).
We have also examined the relative levels of mitoSTAT3 in triple negative breast cancer
cell lines (Figure 31A and Table Rows 2 and 5) compared with ER+, PR+ and/ or HER2+ cells
(Figure 31A and Table Rows 1,3, and 4). The levels of mitoSTAT3 are significantly elevated
in triple negative human breast cancers. Further, analysis of datasets in Oncomine and Cbio
portal point towards an amplification of STAT3 in breast cancer tissue as compared to normal
tissue. There also tends to be amplification of CypD. As CypD may be important for the full
stabilization of mitoSTAT3 (see results above) these two phenomena may be working in concert.
Treatment of a number of different human breast cancer cells with doxorubicin demonstrated a
hormone receptor dependence on the effect of mitoSTAT3. Triple negative human breast cancer
cells surprisingly showed a decrease in mitoSTAT3 levels following treatment (Figure 31B,
panel 1), whereas ER+ and/or Her2+ lines tended to show an increase in mitoSTAT3 after
doxorubicin administration (Figure 31B, panels 2 and 3). The 4T1 cells used above are
generally thought to be of positive hormone receptor status (162)

thereby demonstrating

confluence between the mouse and human studies. These results are also consistent with the
hypothesis that different subtypes of human breast cancer have different levels of mitoSTAT3 as
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a result of differential CypD levels and binding, which may in part explain differences in
aggressiveness and therapeutic sensitivity.
To extend the significance of our findings to other cancers we examined levels of
mitoSTAT3 in multiple myeloma cells. We observed selective increases in mitoSTAT3 in
bortezomib resistant human multiple myeloma cells compared to the sensitive parental line from
which they were derived (163) (Figures 32A and B). In fact, it would appear that the
difference in overall STAT3 levels (whole cell extract (WCE) lanes) between these cells is solely
due to the increase seen in mitochondrial STAT3 (Figure 32D). More STAT3 also associates
with CypD in the bortezomib resistant PS-R multiple myeloma cells (Figure 32C). Bortezomib
is a protease inhibitor used in the treatment of multiple myeloma that is known to induce ROS
production, which under chronic stimulation may recruit STAT3 to the mitochondria (164-166) .
Similar results were obtained when comparing the ovarian cancer cell lines OVCAR3 and
SKOV3, the latter known to be more resistance to cisplatin and radiotherapy (Figure 32E). The
proposed protective effect of STAT3 binding to CypD may also be relevant in radiation therapy,
which is well known to affect mitochondrial function. Irradiation of A549 lung epithelial
adenocarcinoma cells increases the interaction of STAT3 and CypD (Figure 32F). Therapeuticand radio-resistance is unfortunately common and a large contributor to disease recurrence,
thereby driving a need to better understand how cancer cells become refractory to treatment.
These results indicate that accumulation of mitoSTAT3 is a potential mechanism of resistance in
a variety of cancers. Treatment with these stressors that induce chronic adaptive changes by the
cell also further support the idea that there is differential regulation of mitoSTAT3 in the acute
versus chronic setting as explored above (Figure 10).
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Figure 30: Doxorubicin treated cells and tumor bearing mice show selective increases in
mitoSTAT3. Mitochondria (A) or cytosol (B) from 4T1 cells treated with doxorubicin were
immunoblotted for STAT3. Tubulin (cytosol) and CypD or NDUFA9 (mitochondria) were used
to assess purity. (C) Levels of mitoSTAT3 and cytosolic STAT3 were normalized to loading
controls (tubulin or CypD) and quantified by densitometry. (D) Mitochondrial extracts from 4T1
cells either untreated or treated for 24H with doxorubicin were subjected to GST-CypD pulldown. (E) Levels of STAT3 in mitochondria from untreated tumors (PBS control) or tumors
from doxorubicin treated mice (upper panel). Cytosolic levels of STAT3 in the same animals
(lower panel). Levels of STAT3 in the cytosol and mitochondria were quantitated from mice
injected every 7 days with doxorubicin (F) or every three days with doxorubicin (G). *p<0.001,
Student’s T-test. (H) Western blot analysis of mitochondrial lysates from 4T1 derived tumors
treated every 7d, 4d, or 3d with doxorubicin depicting increased mitoSTAT3 with increasing
frequency of drug administration. (I) Metastatic 4T1 cells from the liver were isolated from
digested tissue from animals that were untreated (PBS injection) versus those that received
doxorubicin and isolated mitochondria were immunoblotted for STAT3 (quantification in lower
panel). *4T1 in vivo tumor model done in collaboration with Dr. Kazuaki Takabe, Dr. Ali Razza,
and Dr. Akimitsu Yamada.
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Figure 31: Analysis of mitoSTAT3 and Response to Doxorubicin in a Clinically Relevant
Panel of Human Breast Cancer Cells.
A) Mitochondria were isolated from five different human breast cancer cell lines (see table
below figure) and the mitoSTAT3 levels were normalized to NDUFA9 to determine the relative
mitoSTAT3 levels as depicted in the table. (B) Human breast cancer cells of varying hormone
receptor status were treated with doxorubicin for 48H at their respective IC50 concentration and
mitochondrial and cytosolic extracts were probed for STAT3 and an appropriate loading control
(L.C.: NDUFA9 for mitochondrial fractions, Tubulin for cytosolic fractions).
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Figure 32: Mitochondrial STAT3 and Therapeutic Resistance.
(A) Mitochondrial extracts from bortezomib resistant (PS-R) human multiple myeloma cells and
their sensitive parental counterpart (U266) were probed for STAT3. The mitochondrial protein
NDUFA9 is presented as a loading control. (B) Cytosolic extracts from PS-R and U266 cells
probed for STAT3. (C) GST-CypD pulldown of STAT3 from mitochondrial extracts prepared
from PS-R (R) or U266 (U) cells. (D) Whole cell extract (WCE), cytosolic, mitochondrial, and
nuclear fractions from PS-R (R) and U266 (U) cells. (E) Mitochondrial and cytosolic extracts
prepared from OVCAR3 (OV) and SKOV3 (SK-radiation and cisplatin resistant) ovarian
carcinoma cells were probed for STAT3 and the indicated loading control. (F) Mitochondrial
extracts prepared from A549 human lung epithelial adenocarcinoma cells untreated or subjected
to 5Gy radiation and GST-CypD pulldown of STAT3.
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DISCUSSION

I. Dynamic Regulation of mitoSTAT3
Increasingly, a number of proteins not classically associated with the mitochondria are
now being implicated as having important functional roles there (4) . Though traditional
mitochondrial targeting and subsequent import of mitochondrial proteins has been predicated on
those proteins containing a mitochondrial localization sequence, it is now appreciated that up to
50% of the proteins found in the mitochondria lack this sorting sequence (167) . STAT3, like
other nuclear transcription factors found at the mitochondria, falls into this class, making
characterization of STAT3’s mitochondrial regulation challenging. In this study we have
demonstrated for the first time that mitoSTAT3 levels are acutely regulated and tightly
controlled in response to a number of stimuli. Upon treatment of cells mitoSTAT3 initially
decreases, an event that is likely mediated by proteolytic events. This is followed by a reequilibration of mitoSTAT3 levels contingent upon new protein synthesis and S727
phosphorylation of STAT3. Intriguingly, the recovery phase of mitoSTAT3 is also correlated
with its initial interaction with CypD, an association that seems to be maintained until
mitoSTAT3 levels return to the pre-stimulated baseline.
The understanding of how mitoSTAT3 levels are regulated is an important hurdle in fully
targeting STAT3’s mitochondrial actions. As it is important for both cardioprotection in
ischemia-reperfusion injuries (17, 42, 54, 139, 168) and transformation and growth of cancer
cells (2, 33, 38, 157, 158) , knowing how to selectively increase or decrease mitoSTAT3 levels
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could be an extremely valuable tool in combating these pathological states. Certain
pharmacological treatments have been shown to affect mitoSTAT3 expression, though their
widespread use in studying the mitochondrial STAT3 pathway remains to be determined (38,
169) . Prior reports have also demonstrated that STAT3’s mitochondrial localization can be
altered during cell differentiation (15, 106) , with ROS being linked to decreased mitoSTAT3
levels (106) . STAT3 levels are also known to increase in the mitochondria under chronic
stimulation with both cytokine (15) and growth factor stimulation (31, 102) to drive T-cell
activation and axonal growth alike. With the results presented here it would suggest that
mitoSTAT3 levels are differentially regulated in the acute versus chronic setting. MitoSTAT3 is
also known to be important in the proliferation of embryonic stem cells, where it supports
oxidative phosphorylation to couple STAT3’s transcriptional effects in maintaining pluripotency
(142) . Fine-tuning mitochondrial STAT3’s levels then may be important in controlling
mitochondrial adaptation to the real-time demands of the cell.
Currently, the fate of mitoSTAT3 following stimulation is unknown, though the most
probable explanation is that it is rapidly degraded. Though we have attempted to target some of
these proteases chemically, it is plausible that they inefficiently enter the mitochondria, therefore
potentially masking any effect. Both p50 and IκBα have been shown to be lost from the
mitochondria following stimulation with TNFα, with IκBα likely being degraded following
phosphorylation in part by a calpain-dependent mechanism (170) . While STAT3’s degradation
may be linked with its phosphorylation status (171) and calpains are known to target and cleave
STAT3 (114) , we did not see any effect of calpain inhibition on treatment induced mitoSTAT3
loss. Targeting both Lon and ClpP proteases, the two major serine proteases in the mitochondria,
has been shown to be a viable therapeutic strategy for cancer cell killing by affecting

	
  
147	
  

mitochondrial function and homeostasis (89, 117, 118, 172) . More well-studied in the
mammalian setting than ClpP, Lon protease has been shown to be essential for protein quality
control, turnover, and regulation of mitochondrial dynamics in response to varied stimuli (173175) . However, using both pharmacological and genetic approaches, blockade of these
proteases did not attenuate mitoSTAT3’s loss. There are a number of other mitochondrial
proteases, including inner membrane associated mitochondrial AAA proteases, which are
emerging as important targets (116) that may be the primary driver for the initial changes we
observe in mitoSTAT3. Moreover, simultaneous blockade of multiple protease pathways may be
necessary as inhibition of a single cascade may lead to altered enzymatic activity and
compensation by another protein. Consistent with this, inhibition of Lon protease alone in HeLa
cells shows no gross changes in mitochondrial function or protein content due to increased
activity from another ATP dependent protease (176) .
Though proteolysis of mitoSTAT3 would be most consistent with the kinetics of the
decrease in mitoSTAT3 we have observed, it is clear that signal transduction originating from
the plasma membrane can have rapid downstream consequences at the mitochondrial level. Here
we have demonstrated that aside from H2O2, which has broad effects on intracellular signaling
cascades, cytokines can also regulate mitoSTAT3. A number of kinases, including Akt, ERK,
and JNK, have been reported to exist in the mitochondria where they regulate mitochondrial
dynamics via phosphorylation events (177-179) . In fact, translocation of Akt to the
mitochondria can occur within minutes of stimulation by insulin or insulin-like growth factor 1
lending support to the rapid responses we have observed here in changes in mitoSTAT3 (180) .
Inhibition of a number of these signaling pathways alone did not have an effect on mitoSTAT3,
though it is probable that multiple kinases converge on STAT3 here. One mechanism that we
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have yet to explore is the potential role of lipid raft mediated signaling events driven by caveolin
in regulating mitoSTAT3. ERK is recruited to the mitochondria following activation in a lipid
raft dependent manner (181) , and mitoSTAT3 itself may be modulated by lipid raft signaling
driven by caveolin-3 containing micro-domains (56) . The association of lipid rafts with
mitochondria has been shown to be an important event in the cells response to stress (182) ,
which may serve as an important signaling platform in controlling mitoSTAT3.
An alternative explanation for the reported mitoSTAT3 loss here is that it is trafficked to
another cellular compartment. Signaling to the nucleus would be an attractive target, especially
considering STAT3’s well-established role as a nuclear transcription factor. Under the
conditions used here, STAT3 is potently recruited to the nucleus following stimulation. It is
difficult to assess the contribution that the mitochondrial pool of STAT3 might have here
considering STAT3’s abundant cytosolic expression. Other mitochondrial proteins, including
the pyruvate dehydrogenase complex and SSBP1, have been reported to translocate from the
mitochondria to the nucleus to regulate transcription under conditions of stress (143, 144) .
While this is unlikely the case for mitoSTAT3, especially considering the results obtained with
cells exclusively expressing mitochondrial localized STAT3, we cannot completely rule this
possibility out at this time. Another possibility is that mitoSTAT3 is removed from
mitochondria following stimulation through the PINK1-Parkin dependent mitochondrial derived
vesicle (MDV) pathway (183, 184) . These vesicles tend to remove damaged mitochondrial
cargo for transport to the lysosome and hence, are emerging as important players in
mitochondrial quality control (185) . Tom20 is recognized as a mitochondrial protein that is
trafficked through these MDVs, and STAT3 is reported to interact with Tom20 (42) . Whether
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or not the STAT3-Tom20 association is part of mitoSTAT3’s import into the mitochondria or is
part of this vesicular clearance pathway remains to be determined.
Though not studied as of yet, MDVs might play a role in transport of mitochondrial
proteins to other cellular locations, potentially as part of the mitochondrial retrograde signaling
pathway. The notion that mitochondria communicate with the nucleus makes adaptive sense
considering that a large fraction of mitochondrial proteins are transcribed in the nucleus.
Somehow then the nucleus needs a way to assess the current status of the mitochondrial pool in
order to supply the necessary proteins to maintain functional mitochondria. The nature of this
pathway has been elegantly demonstrated in C. Elegans, where the protein ATFS-1 serves as the
link between coordinating the mitochondrial and nuclear programs (145, 186, 187) . A similar
pathway has remained elusive in mammalian biology. It is thought though that signaling
molecules such as ROS or Ca2+ released from mitochondria might activate pathways (like JNK)
to drive the mitonuclear crosstalk (86) . STAT3 not only modulates mitochondrial ROS
production (17, 33, 104, 106, 168) , but also directly regulates mitochondrial calcium content
(15) . The localization of STAT3 to the mitochondria might also affect the phosphorylation
status of nuclear STAT3, suggesting an intimate link between these two subcellular locations
(33) . It is intriguing to think that mitoSTAT3, as well as other transcription factors that localize
to the mitochondria such as p65 and p53, might be part of this communication pathway. This
idea is at least partially supported by the dynamic regulation that we see in mitoSTAT3 levels.
In fact, we have also observed a decrease in p65 levels in the mitochondria following H2O2
stimulation (data not shown).
CypD has been reported to play a role in this retrograde signaling cascade and it was
shown that is mediated through its effects on STAT3 activation (85) . This is interesting, as we

	
  
150	
  

have noted that mitoSTAT3 inducibly binds to CypD following stimulation. This likely
coincides with mitoSTAT3’s return to the mitochondria, as part of its proper folding after
mitochondrial import, though the signaling implications of this association can’t be disregarded.
MitoSTAT3 has previously been shown to associate with CypD basally in heart mitochondria,
where it was reported to play a role in regulation of MPTP sensitivity (42) . Surprisingly, we
observed that S727 in STAT3, which has been heavily implicated in its mitochondrial action,
was dispensable for at least the binding of mitoSTAT3 to CypD. Rather, the N-terminus of
STAT3 was required, pointing to other domains in mitoSTAT3 as being relevant for its noncanonical mitochondrial role. We can’t exclude the possibility at this time, however, that
CypD’s peptidyl-prolyl isomerase activity isn’t dependent upon S727 phosphorylation of
STAT3; especially as S727 is immediately followed downstream by a proline and prolyl
isomerase’s tend to target pS/T-P sites (81) . With the implementation of our novel cell free
system for studying this mitochondrial-signaling cascade, we will be able to more effectively
explore those proteins that are involved in this regulation and their respective post-translational
modifications going forward.
Though the functional implications of this pathway and binding to CypD are not explored
in depth here, we anticipate that this will be linked to STAT3’s mitochondrial role. This could
be either indirectly by assisting in proper folding of mitoSTAT3 or via direct effects of
mitoSTAT3 on the MPTP. Future work will clarify the implications of this protein-protein
interaction. Of note the mitochondrial actions of STAT3, particularly on the activity of the ETC,
have been questioned due to the stoichiometric difference in the amount of mitochondrial
complex proteins as compared to levels of mitoSTAT3 (13) . However, mitoSTAT3’s
interaction with CypD may serve as a representative protein interaction that could have a
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significant impact on mitochondrial function, akin to p53’s reported regulation of MPTP via
CypD binding (48) . Interestingly, a recent report suggests that expression of CypD is necessary
for Ras transformation and tumorigenesis (188) . Considering also the necessity of mitoSTAT3
in Ras transformation (2) it is tempting to speculate that CypD’s requirement in this process is
through its binding and stabilization of the mitoSTAT3 pool.
The dependence of the recovery of mitoSTAT3 after stimulation on S727
phosphorylation is in concert with a prior report that demonstrated the S727 site was important
for its mitochondrial import (6) . The fact that we see no noticeable defect in basal mitoSTAT3
levels when S727 is mutated to an alanine suggests though, that there are likely other means of
bypassing this import requirement that become compromised under conditions of stress. Though
the MEK-ERK pathway is known to activate STAT3 at S727 and it has been linked to regulating
the mitochondrial pool of STAT3 (7, 102) , MEK and ERK inhibition had no effect on the
observations here. This is not entirely surprising as a number of other kinases can phosphorylate
STAT3 at this residue, and there is likely a large degree of crosstalk between multiple signaling
pathways here. Strikingly, the full recovery of mitoSTAT3 was blunted when protein synthesis
was inhibited. This is in spite of the large cytoplasmic pool of STAT3 that is still present under
these conditions. Either the chaperone protein that is responsible for the translocation of STAT3
to mitochondria has a short half-life or there is a limited fraction of STAT3 that is competent to
go to the mitochondria. The latter idea is interesting, as for p53 there exists a distinct
mitochondrial isoform of the protein (189) . Other isoforms of STAT3 have been reported but
to date there is no information on whether or not they, or others, are mitochondrially relevant
(190) .
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There exists a wealth of information on the functional importance of mitoSTAT3, which
includes effects on the ETC, ATP production, mitochondrial ROS generation, mtDNA
regulation, mitochondrial Ca2+ content, and MPTP susceptibility. Together this regulation drives
normal biological processes and pathological states alike. We now add to and extend those
findings by describing a novel-signaling pathway that acutely regulates mitoSTAT3 and drives
its association with CypD. Further characterization of this cascade and how mitoSTAT3 is
regulated will provide greater insight into how to effectively target the mitochondrial pool of
STAT3 for the purposes of promoting health and combating disease.

II. mitoSTAT3 Regulation and CypD Association in Controlling Mitochondrial Function
Even though we have seen clear effects on mitoSTAT3 levels and its binding to CypD,
the downstream consequences of this pathway from a functional perspective have been difficult
to tease out. STAT3 has been implicated in virtually every mitochondrial function since its
original discovery in this organelle. Considering the induction of an association between
mitoSTAT3 and CypD that we observed we thought that STAT3 would have clear effects on
MPTP regulation. However, the results were mixed, and direct measurement of the
susceptibility of the pore to opening via calcium retention capacity (CRC) assays showed only
mild defects in pore functioning in the absence of STAT3. This has made more concrete
determinations about the role of STAT3 in MPTP regulation challenging. Prior work from heart
mitochondria had demonstrated that STAT3 could regulate the MPTP, but only under conditions
of actively respiring mitochondria (42) . Similarly, in an ischemia-reperfusion injury model,
mice expressing a mitochondrial targeted and transcriptionally inactive form of STAT3
suppressed permeability transition in the early reperfusion period, which is the key interventional

	
  
153	
  

window for limiting infarct size (139) . However, these animals express mitochondrial STAT3
to a level that is far beyond physiological and as such, may have broader control of
mitochondrial biology than endogenous protein. And though inhibitors against STAT3 have
shown similar results in a number of cardiac models (17) , these compounds tend to target the
SH2 domain of STAT3, which is dispensable for its mitochondrial action (1, 2) , and points to
off target effects of these compounds. In this light, and considering the work presented here, it is
now likely that STAT3’s actions at the MPTP are an indirect consequence of its role in
controlling other mitochondrial functions like electron transport chain activity.
We now believe that the association of mitoSTAT3 with CypD may instead be a
reflection of its import and proper folding at the level of the mitochondria. Few reports though
have investigated this important functional role of CypD, as most focus on its regulation of the
permeability transition pore. However, treatment with CsA, an inhibitor to CypD, drives a
mitochondrial unfolded protein response (121) indicating the importance of this protein in
maintenance of the mitochondrial proteome. Classical import of mitochondrial proteins requires
their unfolding as they navigate the mitochondrial membrane import and sorting complexes,
necessitating their re-folding within the mitochondria in order to be functional (191) .
Importantly, to expedite the process, protein complexes are involved in both the import and
folding pathways, and CypD is known to associate with a number of other mitochondrial
chaperones, likely for this purpose (137, 138) . Presumably, CypD’s role in this process is
dependent on its peptidyl prolyl isomerase activity, which has been shown to play important
roles in regulating protein phosphorylation, stability, localization, and activity (81) . STAT3 has
been shown to interact with other members of the cyclophilin family (192) and isomerization of
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STAT3 is an important player in its nuclear localization (83) . This sets the stage for a role of
CypD in regulating mitoSTAT3 levels and function, which will be the focus of future studies.
Most studies that have investigated mitochondrial STAT3 have observed a defect in
electron transport chain activity in its absence. We attempted to integrate this regulation as part
of the consequence of the dynamic changes that we have reported here in mitoSTAT3 levels
after stimulation. However, no significant changes in oxygen consumption were noted after
OSM stimulation. This is consistent with published data showing IL-6 treatment of cells did not
affect oxygen consumption or electron transport chain activity, despite its modulation of
mitoSTAT3 (15) . Rather they showed that under these conditions mitoSTAT3 was recruited to
mitochondrial supercomplexes where it was important for coupling mitochondrial membrane
potential with increasing intra-mitochondrial calcium content. We explored each of these
possibilities, but found no consistent changes that were shared between cytokine treatment and
oxidative stress, two conditions that similarly affect mitoSTAT3. This was particularly the case
in terms of mitochondrial membrane potential, mitochondrial ROS production, and
mitochondrial calcium handling where we observed robust changes upon H2O2 treatment, but no
effects with cytokine administration. One key miss step in these studies though may be our
focus on the acute functional changes that are associated with mitoSTAT3’s loss, recovery, and
subsequent binding to CypD. Instead, these acute regulatory events may prime the system and
only lead to observable functional changes in the chronic setting.
The other challenge in ascertaining a biological role of these signaling events are the
clear discrepancies in mitoSTAT3’s actions amongst different cellular systems. For instance, in
a keratinocyte model, mitoSTAT3 suppresses mtDNA to decrease mitochondrial-encoded
transcripts (107) , whereas it is essential for promoting mitochondrial transcription in embryonic
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stem cells (142) . Mitochondrial STAT3 has also been reported to affect every electron
transport chain complex activity, with the exact complex targeted being entirely cell dependent.
Original work by our lab showed that pro-B cells lacking STAT3 had defects in Complex I and
II activities of the ETC exclusively (1) , but Ras transformed cells lacking STAT3 also had
compromised Complex V activity (2) . Other reports have now demonstrated that STAT3 can
affect the activity of Complexes III and IV (9, 10) , and in some cases cause a localized defect
exclusively at Complex IV of the ETC (102) . Clearly, then, mitochondrial STAT3’s function is
both highly cell specific and context dependent, making broader conclusions about its overall
function as we have attempted here difficult. This is readily apparent in the differences we have
observed in the dependence of mitochondrial membrane potential on mitoSTAT3 between
various cell lines (Figure 26D). In spite of this, the hope is that by understanding the signaling
events regulating mitoSTAT3 and its interacting partners, like CypD, one will be able to readily
investigate the multitude of mitoSTAT3’s actions despite the cellular system being studied.
Surprisingly, the association of STAT3 with CypD is mediated through its N-terminus
rather than the S727 site that most studies have focused on as being important for the function of
mitoSTAT3. Though we have narrowed the site down to likely somewhere in the N-terminal
domain (NTD), further work is needed to uncover exactly how these two proteins interact. Only
then can one readily test how mitoSTAT3 binding to CypD ultimately regulates and determines
mitochondrial biology. This information will help considerably in resolving the inconsistencies
we have observed up to this point in mitochondrial functional parameters. The discrepancies we
have observed in trying to narrow down the binding site are probably largely reflective of the
over-expression systems we are utilizing in order to study this protein-protein interaction. They
could also be indicative of a structural pocket that is necessary for efficient binding of
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mitoSTAT3 to CypD. This is known to be the case for p53’s association with CypD (193) .
And though the structure of the NTD between STAT3 and STAT1 is remarkably conserved
(194) , peptide inhibitors targeted against the N-terminus of these proteins show complete
specificity (195) . This suggests that there may be subtle structural differences between
mitoSTAT3 and mitoSTAT1 that determines binding to CypD. Initial attempts to explore this
possibility have been unsuccessful as selective deletion of two regions in the NTD that were
unique to STAT3 failed to affect mitoSTAT3-CypD interactions (data not shown). Work is
ongoing to clarify how these two proteins interact.
The possible involvement of the NTD of STAT3 here is intriguing, especially in the
context of mitochondrial retrograde signaling. The NTD of STAT3 regulates a distinct subset of
nuclear encoded genes (194, 196) , which includes the protein C/EBP Homologous Protein
(CHOP), which is known to bind to and regulate genes with a mitochondrial response element to
control mitohormesis (197) . In the absence of CypD, mitochondrial retrograde signaling to the
nucleus is driven through STAT3 (85) though the importance of the NTD of STAT3 was not
explored here. Since we now show that CypD may be required for the stability of mitoSTAT3,
and STAT3’s cleavage sites for degradation tend to be C-terminal leaving the N-terminus intact
(113, 114) , it is plausible that mitochondrial degradation fragments of STAT3 signal to the
nucleus. This is precisely how ATFS-1 functions to regulate mitochondrial retrograde signaling
in C. Elegans (186) .
Consistent with this idea, we demonstrated a basal decrease in genes related to the
mitochondrial unfolded protein response, which is an important contributor to mitochondrial
retrograde signaling, in cells lacking STAT3. As expected then, STAT3 null cells were more
susceptible to mitochondrial clearance under conditions of stress. This suggests that in the
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absence of STAT3 mitochondria may be more damaged and hence, more likely to undergo
mitophagy. Indeed, mitochondria from cardiomyocytes lacking STAT3 are swollen with
disordered cristae even under basal conditions (10) . Though STAT3 is known to suppress
autophagy and the autophagy machinery is used to clear damaged mitochondria as well (146),
STAT3’s role in mitophagy has not yet been characterized. Interestingly, STAT1 is thought to
repress mitophagy, though the exact mechanism is unclear (198) . Classically, mitophagy is
driven through the actions of the serine/threonine kinase PINK1, which phosphorylates both
ubiquitin and the E3 ubiquitin ligase Parkin, to promote the accumulation of ubiquitin on the
outer mitochondrial membrane as an ‘eat me’ signal for the autophagosome (160) . Certain
adapter proteins are also required though to drive the fusion of damaged mitochondria with the
autophagosome including the BH3 containing protein BNIP3, a key mitophagy regulator (160) .
STAT3 is known to regulate the levels of BNIP3 (199) , which we have verified here, pointing
to one mechanistic link between STAT3 and mitophagy.
Besides being important for normal cellular homeostasis, both autophagy and mitophagy
alike have been linked to cancer cell biology and chemotherapy treatment (200) . In studying the
regulation of mitoSTAT3 we noted that chronic stimulation of cells instead lead to an increase in
STAT3 in the mitochondria consistent with previous reports (15, 31, 102) . There is a large
body of data that implicates STAT3 as being important in the development of therapeutic
resistance, particularly with a number of chemotherapy treatments (152, 156, 201-203) . This is
especially the case with the anthracycline drug doxorubicin, whose actions are known to effect
mitochondrial structure and function to lead to cell toxicity (204, 205) . We demonstrate here
that mitochondrial STAT3 levels increase in the mitochondria following doxorubicin
administration using both cell culture and animal models. We anticipate that this is an adaptive
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response to combat the increased mitochondrial dysfunction that arises in the context of
treatment, and seeks to drive therapeutic resistance. One of the biggest changes that has been
noted with doxorubicin treatment is the potent induction of mitochondrial ROS (203, 206, 207) .
One potential function of mitoSTAT3 under these circumstances may be then to offset this
increased oxidative stress by dampening reactive oxygen species production through regulation
of the activity of the ETC. MitoSTAT3 assumes a similar role in ischemia to protect
cardiomyocytes from excessive ROS (11) . Moreover, mitoSTAT3 itself can potentially quench
ROS through an oxidation-reduction cycle mediated by peroxiredoxin (105) .
Though we have struggled to correlate mitoSTAT3 with regulation of the MPTP, this
may be an important mechanism driving STAT3’s involvement in doxorubicin resistance.
Insensitivity of the MPTP to opening is a hallmark of therapeutically resistant cancer cells (208,
209) . This may explain why we also see increased mitoSTAT3 levels, along with binding to
CypD, in other therapeutically resistant cancer cell lines, including bortezomib-resistant multiple
myeloma cell lines. A more careful understanding of how mitoSTAT3 is recruited to the
mitochondria and its functional significance in the context of chemotherapy treatment may
provide useful information in therapeutically targeting it. This is especially important as a large
limitation of doxorubicin treatment is due to its cardiotoxic effects resulting from cardiomyocyte
mitochondrial dysfunction (205) . Interestingly, mitoSTAT3 levels have been shown to
decrease upon doxorubicin treatment in the heart, and attenuating this loss provides
cardioprotection (169) .
This sets up a scenario where mitoSTAT3’s differential regulation in the tumor
microenvironment, as compared to normal tissue, leads to enhanced pathology in the context of
treatment. As traditional STAT3 inhibitors that target its nuclear role have remained largely
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unsuccessful clinically (103) , the need for new approaches that also target mitochondrial
STAT3’s actions seem like an important next step. It will be important going forward, however,
to assess how targeting mitoSTAT3 in a cancer model could potentially lead to harmful effects
on normal biological processes. Though therapeutic side effects can now be limited by directing
therapies directly to cancer cells via nanomedicine, a greater understanding of the signaling
pathways and binding partners of mitoSTAT3, as we have attempted to elucidate here, will allow
for more careful regulation and control of mitoSTAT3.

III. Significance, Future Directions, and Conclusions
A. Significance
The studies presented here provide for the first time an in depth look into the acute
control of mitoSTAT3 that has previously been unappreciated. The robust decrease we see in
mitoSTAT3 after stimulation by cytokines or oxidative stress parallels STAT3’s acute phase
nuclear response. We also now provide insight into how mitoSTAT3 is trafficked to the
mitochondria, an event that is dependent upon new protein synthesis and S727 phosphorylation.
Though mitoSTAT3 has been shown to interact with other mitochondrial proteins, including the
peptidyl prolyl isomerase CypD, we demonstrate that mitoSTAT3’s association with CypD is
inducible and coincides with mitoSTAT3’s re-accumulation in the mitochondria. We anticipate
that this protein-protein interaction plays a critical role in the stabilization of the mitoSTAT3
pool. The N-terminus of STAT3, a region that has not been demonstrated until now to have any
significance in mitoSTAT3 biology, mediates binding of mitoSTAT3 to CypD. All together this
points to a novel signaling cascade that couples cellular signaling events with those of the
mitochondria. Though the functional implications of this cascade are still being teased out, this
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model system provides an unparalleled opportunity to further explore how mitoSTAT3 levels are
controlled. This knowledge will be especially important in order to effectively target
mitoSTAT3 therapeutically.

B. Future Directions
Despite the advances we have made here a number of essential questions still remain,
particularly in regards to the fate of mitoSTAT3 following stimulation. Based on what we have
observed in STAT3 null cells expressing mitochondrial targeted STAT3, it is most likely that
mitoSTAT3 is degraded. To more fully test this, both Lon and ClpP protease can be inhibited
simultaneously to prevent any compensatory effects from either protein when they are targeted
individually (176) . A more elaborate means to examine this would be to incorporate the newly
described APEX (ascorbate peroxidase) biotin labeling method to identify changes in
mitoSTAT3 levels. This has previously been used to analyze the mitochondrial proteome
following its mitochondrial targeting (210) , and has even been shown to be an applicable
technique in tracking mitoSTAT3 following growth factor stimulation (102) . In either case, we
would expect to see decreases in mitoSTAT3 labeling rapidly after stimulation with signal
recovery in time. The alternative, but less likely scenario, is that mitoSTAT3 is exported from
the mitochondria and trafficked to another intracellular compartment. Traditional
immunofluorescence techniques have been challenging to assess mitoSTAT3 due to the large
signal emanating from cytosolic STAT3. Further, flurophore conjugation to STAT3 with GFP or
dsRed has not been successful in detecting mitochondrial STAT3 (80) . A possible way around
this limitation is to gently permeabilize the plasma membrane to essentially wash out the
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cytosolic STAT3 signal and then stain for mitoSTAT3, an approach that has been readily used to
ascertain the mitochondrial dynamics of the GTPase Arl2 (211) .
Support for the degradation of mitoSTAT3 also comes from the presence of
immunoreactive cleavage fragments of STAT3, which appear to be selective to the
mitochondrial pool. After stimulation, we are able to detect a small percentage of these
fragments in the nucleus (data not shown), though we can’t rule out at this time whether or not
they are preparation artifacts, which has previously been an issue in studies on STAT3 (212) .
Assuming these products are real, they represent an intriguing target as they may be functionally
related to the cleaved peptides that regulate the mitochondrial retrograde signaling pathway and
the unfolded protein response in C. Elegans (145) . Under those conditions, the mitochondrial
peptide exporter HAF-1 regulates translocation of cleaved mitochondrial peptides into the
cytosol, which act as important signaling molecules to regulate mitochondrial protein import
(186) . The mammalian homolog to HAF-1, the mitochondrial transporter ATP binding cassette
10 (ABCB10), has been virtually uninvestigated, though it may be linked to mitochondrial ROS
production and its deletion is embryonically lethal (213, 214) . It would be interesting to
knockdown expression of ABCB10 in a number of our cell culture models and explore not only
how it affects the abundance of cleaved mitoSTAT3, but also whether or not it impacts the
regulation of mitoSTAT3 we have observed.
Similarly, the recovery phase of mitoSTAT3 needs to be more carefully explored,
especially in regards to how STAT3 is trafficked to the mitochondria. Currently, our
understanding of how STAT3 is directed to the mitochondria (considering that it lacks the typical
mitochondrial targeting sequence) and subsequently imported is still in its infantile stages. At
least part of STAT3’s mitochondrial localization depends on the complex I protein GRIM-19 and
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S727 phosphorylation of STAT3 (6) . However, this work was all ascertained from in vitro
mitochondrial import assays and may not completely recapitulate what is seen in vivo. That
being said, we present results here that support at least the role of S727 phosphorylation in this
process. Attempts to knockdown GRIM19 have been largely unsuccessful but requires more
effort to determine the relevance of this protein in mitoSTAT3 control. Perhaps the most well
characterized mechanism for mitochondrial trafficking and subsequent import of a non-canonical
mitochondrial protein is for the nuclear transcription factor p53. Mono-ubiquitination of p53 is
followed by its phosphorylation that allows it to be recognized and isomerized by Pin1, which in
turn directs it to the mitochondria (82, 215) . Once there, the mitochondrial disulfide relay
system, which recognizes oxidized cysteine residues in target proteins via CHCHD4, helps
facilitate the import of mitochondrial p53 (216) . As STAT3 associates with Pin1 (83, 84) and
STAT3 has a number of surface exposed cysteine residues (65) we investigated both of these
processes as part of mitoSTAT3’s regulation. The absence of Pin1 and CHCHD4 did not affect
mitoSTAT3 levels or its regulation (data not shown) suggesting mitoSTAT3’s mitochondrial
targeting and import mechanism is distinct from that of p53.
We also have data from mass spectrometry analysis that demonstrates STAT3 interacts
with a number of mitochondrial chaperone proteins, including Hsp60 and the mitochondrial
Hsp90 family member TRAP1. STAT3 is known to associate with Hsp90 (217) so it is likely
to also bind with TRAP1. Immunoprecipitation studies from mitochondrial extracts both at
baseline and after stimulation can be interrogated to determine whether or not these proteins
interact under the conditions where we have observed changes in mitoSTAT3. If this is the case,
knockdown of one of these chaperone proteins may facilitate a better understanding of
mitoSTAT3. This approach is likely to be more fruitful than trying to determine the exact kinase

	
  
163	
  

pathway that mediates mitoSTAT3 targeting via S727 phosphorylation. For one, a number of
kinases are known to phosphorylate STAT3 so even with successful blockade of the key kinase
in this pathway, there is likely to be compensation by another non-major kinase. Coupled with
the issues of non-specificity of inhibitor studies (a complication within in our own studies
presented here) and the fact that S727 phosphorylated STAT3 does not exclusively reside in the
mitochondria, attempting to narrow down the exact signaling events will likely be challenging.
Currently, the greatest obstacle in further demonstrating the significance of what we have
herein observed is the lack of a STAT3 mutant that reproducibly is unable to bind to CypD. The
reason for this is likely the result of over-expression artifacts from the expression vectors and
cell systems we are utilizing. To navigate this problem, constructs can be designed with varying
strength of the CMV promoter in order to optimize protein expression such that it more closely
resembles endogenous protein levels (218) . Further, assuming that a post-translational
modification of STAT3 might be important for CypD binding, mass spectrometry analysis can be
performed on immunoprecipitated STAT3/1S chimeric protein before and after H2O2 treatment.
Utilizing the chimeric construct, which we know strongly associates with CypD, can reduce the
potential sites in STAT3 that might need to be screened. This approach makes a key assumption
that it is STAT3 that is modified and not some adapter protein that is necessary for mitoSTAT3CypD binding. Considering the shared protein signature from mass spec studies on extracts
following GST-CypD pulldown or STAT3 immunoprecipitation though, one could imagine that
the STAT3-CypD interaction is part of a much larger multi-meric complex. This would make
delineation of this protein-protein interaction more challenging and would likely require larger
scale lysate fractionation methods to determine the protein (s) involved in this process. With the
generation and characterization of our cell free system to study mitoSTAT3 and CypD, such
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methods are feasible, as are library siRNA screening approaches, particularly when trying to
address the phosphatase that might be involved in this signaling pathway. There are a number of
reported mitochondrial phosphatases, though the dual specificity phosphatase DUSP2, which is
known to regulate STAT3, and the serine/threonine phosphatase PGAM5, which converges on a
number of mitochondrial pathways, are attractive initial targets (219, 220) .
The functional consequences of what we report here also require greater exploration,
particularly if part of this pathway relates to mitochondrial quality control. As discussed above
though, mitochondrial STAT3’s action will likely be highly dependent on the cell system
studied. This may be one reason why we have struggled to see significant changes in MPTP
regulation driven by mitoSTAT3 despite its association with CypD. Alternatively, as previously
reported, mitoSTAT3 could function upstream of CypD in regulating permeability transition
(42) . With this in mind it would be interesting to knockdown STAT3 in a CypD null
background and see if this restores the cell’s sensitivity to transition pore opening as CypD KO
cells are resistant to MPTP events (120, 221) . What also may be informative is in investigating
mitoSTAT3 in a Parkin null background or where Parkin has been depleted by shRNA. Parkin is
necessary, along with PINK1, to drive the clearance of damaged or dysfunctional mitochondria
(160) . This should rescue the deficiency seen in the mitochondrial response to the promitophagic stimulus of OA (oligomycin and antimycn a) treatment when STAT3 is absent. A
lack of parkin might also help clarify whether or not STAT3 might be removed from
mitochondria following stimulation via the mitochondria derived vesicle (MDV) pathway as
parkin is required to mediate this process (184) .
Perhaps the most intriguing downstream target of mitoSTAT3 signaling and CypD
binding may be in the framework of Ras transformation of cells and tumorigenesis. Until
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recently, the role of CypD in cancer progression had been unclear. Traditionally, due to its wellcharacterized role in promoting permeability transition pore opening (46, 222-224) , CypD has
been thought to solely play a pro-death role. However, there is evidence that expression of
CypD might correlate with hormone receptor positive cancer cell progression, and that it might
even play a key anti-apoptotic function (225, 226) . A recent report also now demonstrates that
CypD is essential for Ras tumorigenesis, as depletion of CypD significantly reduced the growth
of Ras transformed tumors (188) . This is interesting as mitoSTAT3 is also necessary for Ras
transformation of cells (2, 157) . It is conceivable then that the shift in CypD’s role from a prodeath protein to a pro-survival factor in cancer may be dependent on its association with
mitoSTAT3, particularly in light of the results presented here. Therefore, it would be of interest
to test the interdependence of mitoSTAT3 and CypD in promoting Ras tumorigenesis. Cell lines
containing an oncogenic Ras could be readily compared to their non-Ras transformed
counterparts to see if there was any correlation between mitoSTAT3 levels and CypD. One
might expect that blockade of the mitoSTAT3-CypD association would have a greater effect in
cancer cell lines dependent on Ras signaling than those that weren’t. Through knockdown
studies and mutational analysis this could potentially be explored in various human and murine
cancer cell models, and would serve as a nice extension of the work presented here into an
important and relevant functional model.
C. Conclusions
The functional importance of mitoSTAT3 has been explored in great detail, though until
now, its regulation in response to a number of stimuli has remained unclear. The results
presented here provide evidence that mitoSTAT3 is dynamically regulated as summarized in
Figure 33. Initially lost from the mitochondria upon stimulation, mitoSTAT3 levels recover
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with time. Both S727 phosphorylation of STAT3 and protein synthesis are necessary for the
timely and full renewal of the mitochondrial STAT3 pool. Increased binding of mitoSTAT3 to
CypD also marks the recovery phase. Commonly thought of as the key regulator and activator of
the MPTP, CypD serves an important chaperone role in the mitochondria in mediating protein
folding, which we believe is at work here potentially to stabilize STAT3’s mitochondrial
localization. These results also provide a model system to better study the signaling cascades
that regulate mitoSTAT3, as we are able to isolate a period in which STAT3 is actively recruited
to the mitochondria. The development of a cell free system to study mitochondrial proteinprotein interactions should also prove to be a useful tool for studying mitochondrial biology
going forward. Future work will focus on further delineating this novel signaling pathway and
its functional ramifications.
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Figure 33: Working Model of mitoSTAT3 Signaling and CypD Binding.
Upon initial stimulation (left panel) mitoSTAT3 and/or mitoproteases are post-translationally
modified that induces their association and leads to the proteolytic cleavage of mitoSTAT3 and a
decrease in mitoSTAT3 levels. These fragments may be further degraded or may contribute to
extra-mitochondrial signaling. With continued stimulation (right panel) new protein synthesis
(either of STAT3 or a chaperone protein required for STAT3 mitochondrial targeting) couples
with S727 phosphorylation of STAT3 to mediate its mitochondrial targeting. Presumably,
mitoSTAT3 is also tyrosine phosphorylated (pY, non-Y705 site) as following its import into the
mitochondria, mitoSTAT3 is dephosphorylated via a protein tyrosine phosphatase (PTP). This
facilitates its interaction with CypD, which is likely important for mitoSTAT3’s proper folding
and mitochondrial stability and likely determines mitoSTAT3’s downstream effects on the ETC,
MPTP, and ROS production, amongst others. OMM, outer mitochondrial membrane, IMS,
intermembrane space, IMM, inner mitochondrial membrane.
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